TP,Add_to_black_list,FP,candidate,ADJ,count_nct,is_mab,is_therapy,sentence,sents,_ids,link_to_ct_gov
1,,,radioiodine,FALSE,2,FALSE,FALSE,"Surgery is the standard therapeutic approach for patients with differentiated thyroid carcinoma (DTC), followed by radioiodine (RAI) therapy if indicated.","{'Surgery is the standard therapeutic approach for patients with differentiated thyroid carcinoma (DTC), followed by radioiodine (RAI) therapy if indicated.', 'A Phase II Study of the Safety and Effectiveness of rhTSH in Radioiodine Treatment for Patients With Differentiated Thyroid Cancer.', 'Effect of Radioiodine Therapy on Ovarian Reserve in Female Patients With Differentiated Thyroid Cancer.'}","{'NCT04396158', 'NCT04447183'}",NCT04396158
,1,,angiotensin,FALSE,2,FALSE,FALSE,Comparing preventive effect of myocardial global longitudinal strain-based cardioprotective stragety (angiotensin receptor blocker prophylaxis) with left ventricular ejection fraction-based strategy in breast cancer patients treated with adjuvant trastuzumab,"{'Comparing preventive effect of myocardial global longitudinal strain-based cardioprotective stragety (angiotensin receptor blocker prophylaxis) with left ventricular ejection fraction-based strategy in breast cancer patients treated with adjuvant trastuzumab', '- IMN patients with moderate risk and have a decline of less than 50% in proteinuria despite renin-angiotensin system blockade for at least 6 months before randomization.'}","{'NCT04429633', 'NCT04424862'}",NCT04429633
1,,,lu-psma,FALSE,2,FALSE,FALSE,"This clinical trial will evaluate the dosimetry, efficacy and toxicity of Lu-PSMA in men with high PSMA-expressing high-risk localized or locoregional advanced prostate cancer (HRCaP) undergoing radical prostatectomy (RP) and pelvic lymph node dissection (PLND)","{'This clinical trial will evaluate the dosimetry, efficacy and toxicity of Lu-PSMA in men with high PSMA-expressing high-risk localized or locoregional advanced prostate cancer (HRCaP) undergoing radical prostatectomy (RP) and pelvic lymph node dissection (PLND)', 'This phase 2 randomised clinical trial will investigate the activity and safety of adding Lu-PSMA to enzalutamide in patients with metastatic castrate resistant prostate cancer (mCRPC) not previously treated with chemotherapy'}","{'NCT04419402', 'NCT04430192'}",NCT04419402
,1,,64cu,FALSE,2,FALSE,FALSE,The purpose of this study is to assess the performance of imaging agent 64Cu-SARTATE in participants with known or suspected Gastroenteropancreatic (GEP) Neuroendocrine Tumors (NETs) as a potential new way to help diagnose NETs,"{'The purpose of this study is to assess the performance of imaging agent 64Cu-SARTATE in participants with known or suspected Gastroenteropancreatic (GEP) Neuroendocrine Tumors (NETs) as a potential new way to help diagnose NETs', 'Positron Emission Tomography (PET) Imaging of Patients With Low & Intermediate Grade Neuroendocrine Tumors Using 64Cu-SARTATE: A Single Centre, Open-Label, Non-Randomized, Phase-0 Microdosing Investigation.'}","{'NCT04440956', 'NCT04438304'}",NCT04440956
,1,,aza,FALSE,2,FALSE,FALSE,"The study consists of two treatment arms - In one arm, participants will receive venetoclax and AZA.","{'The study consists of two treatment arms - In one arm, participants will receive venetoclax and AZA.', 'Participants in another arm will receive oral doses of placebo tablet and intravenous or subcutaneous AZA solution.', 'The purpose of this study is to see how safe and effective venetoclax and azacitidine (AZA) combination are when compared to AZA and a placebo (contains no medicine), in participants with newly diagnosed higher-risk MDS.', 'Participants in one arm will receive oral doses of venetoclax tablet and intravenous (infusion in the vein) or subcutaneous (given under the skin) AZA solution.', 'In another arm, participants will receive AZA and placebo.', 'In this single arm multi-centers prospective study, adult patients with rrAML are included and treated with BCL-2 inhibitor venetoclax at a dose of 400mg per day for 14 days, combined with azacitidine (AZA) at a dose of 75mg/m2 per day for 7 days, and HHT 1mg/m2 per day for 7 days, and then the eficacy and safety of HVA regimens as salvage treatment in rrAML are assessed'}","{'NCT04424147', 'NCT04401748'}",NCT04424147
1,,,cb-5339,FALSE,2,FALSE,FALSE,"- CB-5339 will be administered orally on a schedule of once daily, 4 days on and 3 days off, in 28-day cycles.","{'- CB-5339 will be administered orally on a schedule of once daily, 4 days on and 3 days off, in 28-day cycles.', 'This is a multicenter, open-label Phase 1 study of orally administered CB-5339 in participants with R/R AML or participants with R/R intermediate- to high-risk MDS', 'A Phase 1 Trial of the p97 Inhibitor CB-5339 in Patients With Advanced Solid Tumors and Lymphomas.', '-To establish the safety, tolerability, and recommended phase 2 dose (RP2D) of CB-5339 administered orally on a schedule of once daily, 4 days on and 3 days off, in patients with advanced solid tumors and lymphomas Secondary Objectives: - To evaluate the pharmacokinetic profiles of CB-5339 - To assess the preliminary antitumor activity of CB-5339 in patients with advanced solid tumors and lymphomas - To determine the effects of CB-5339 on the ubiquitin proteasome system and markers of cell death in pre- and post-treatment tumor biopsies and peripheral blood mononuclear cells (PBMCs) Exploratory Objectives: -To evaluate potential associations between CB-5339 activity and genomic alterations assessed in circulating tumor DNA Eligibility: Patients >= 18 years of age must have histologically documented solid tumors whose disease has progressed on standard therapy or for which there is no available standard therapy or therapy known to prolong survival;', '- The p97 inhibitor CB-5339 has been well characterized in in vitro and in vivo studies and had demonstrated induction of an unfolded protein response, decreased cell viability, and apoptosis.', '- Pharmacodynamic effects of CB-5339 will be assessed through a panel of markers including accumulation of lysine-48 (K48) specific polyubiquitinated substrates in the cytosol, upregulation of transcription factor CHOP in nucleus, and appearance of cleaved caspase-3 in the cytosol', 'A Phase 1 Study to Evaluate the Safety and Pharmacokinetic Profiles of CB-5339 in Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed/Refractory Intermediate or High Risk Myelodysplastic Syndrome.'}","{'NCT04449562', 'NCT04402541'}",NCT04449562
,1,,prednison,FALSE,2,FALSE,FALSE,"The investigators used TPM regimen (thalidomide + prednison + methotrexate ) to treat LGLL since 2013, and 18/20 patients (90%) obtained clinical response, including 80% complete response.","{'The investigators used TPM regimen (thalidomide + prednison + methotrexate ) to treat LGLL since 2013, and 18/20 patients (90%) obtained clinical response, including 80% complete response.', 'a phase I trial focusing on safety and efficacy of prednison shock plus sirolimus maintenance in treating Kaposiform hemangioendothelioma (KHE) with Kasabach-Merritt phenomenon (KMP)'}","{'NCT04453345', 'NCT04409691'}",NCT04453345
,1,,antinib,FALSE,1,FALSE,FALSE,"It is a single-arm, multicenter phase II clinical study of oral etoposide combined with antinib in the treatment of recurrent or metastatic triple-negative breast cancer","{'It is a single-arm, multicenter phase II clinical study of oral etoposide combined with antinib in the treatment of recurrent or metastatic triple-negative breast cancer'}",{'NCT04452370'},NCT04452370
1,,,lutetium-177-psma,FALSE,1,FALSE,FALSE,Lutetium-177-PSMA-I&T Radioligand Therapy in Oligo-metastatic Hormone Sensitive Prostate Cancer.,{'Lutetium-177-PSMA-I&T Radioligand Therapy in Oligo-metastatic Hormone Sensitive Prostate Cancer.'},{'NCT04443062'},NCT04443062
1,,,dsp107,FALSE,1,FALSE,FALSE,Part 2: Preliminary efficacy assessment of DSP107 single agent treatment and DSP107 in combination with atezolizumab in second line treatment of non small cell lung cancer,"{'Part 2: Preliminary efficacy assessment of DSP107 single agent treatment and DSP107 in combination with atezolizumab in second line treatment of non small cell lung cancer', 'Phase I/II Study of DSP107 in Subjects With Advanced Solid Tumors Including a Dose-escalation Safety Study (Part 1) and Preliminary Efficacy Assessment of DSP107 as Monotherapy and in Combination With Atezolizumab (Part 2).', 'Part 1: A first-in-human, open-label, Phase I dose escalation study of DSP107 monotherapy and combination therapy with atezolizumab in patients with advanced solid tumors.'}",{'NCT04440735'},NCT04440735
,1,,hva regimens,FALSE,1,FALSE,FALSE,"In this single arm multi-centers prospective study, adult patients with rrAML are included and treated with BCL-2 inhibitor venetoclax at a dose of 400mg per day for 14 days, combined with azacitidine (AZA) at a dose of 75mg/m2 per day for 7 days, and HHT 1mg/m2 per day for 7 days, and then the eficacy and safety of HVA regimens as salvage treatment in rrAML are assessed","{'In this single arm multi-centers prospective study, adult patients with rrAML are included and treated with BCL-2 inhibitor venetoclax at a dose of 400mg per day for 14 days, combined with azacitidine (AZA) at a dose of 75mg/m2 per day for 7 days, and HHT 1mg/m2 per day for 7 days, and then the eficacy and safety of HVA regimens as salvage treatment in rrAML are assessed'}",{'NCT04424147'},NCT04424147
,1,,hb,FALSE,1,FALSE,FALSE,"In order to blind the investigator, medications are named as ""A"" for syrup of HB and B for placebo.","{'In order to blind the investigator, medications are named as ""A"" for syrup of HB and B for placebo.'}",{'NCT04426435'},NCT04426435
1,,,jsp191,FALSE,1,FALSE,FALSE,A Phase 1 Study to Evaluate the Safety and Tolerability of JSP191 in Combination With Low Dose Radiation and Fludarabine in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia Undergoing Hematopoietic Cell Transplantation.,{'A Phase 1 Study to Evaluate the Safety and Tolerability of JSP191 in Combination With Low Dose Radiation and Fludarabine in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia Undergoing Hematopoietic Cell Transplantation.'},{'NCT04429191'},NCT04429191
1,,,4scar-276,FALSE,1,FALSE,FALSE,Multicenter Trial of Phase I/II Studies on CD276 (B7-H3) Positive Solid Tumors Treated With 4SCAR-276.,"{'Multicenter Trial of Phase I/II Studies on CD276 (B7-H3) Positive Solid Tumors Treated With 4SCAR-276.', 'This study will evaluate the side effects and effective doses of 4SCAR-276 in treating refractory and/or recurrent tumors'}",{'NCT04432649'},NCT04432649
1,,,aic100,FALSE,1,FALSE,FALSE,A Multi Center Phase I Study of AIC100 in Relapsed and/or Refractory Advanced Thyroid Cancer and Anaplastic Thyroid Cancer.,{'A Multi Center Phase I Study of AIC100 in Relapsed and/or Refractory Advanced Thyroid Cancer and Anaplastic Thyroid Cancer.'},{'NCT04420754'},NCT04420754
,1,,antharcycline,FALSE,1,FALSE,FALSE,This study will evaluate the efficacy and safety of antharcycline-based adjuvant chemotherapy compared with observation in triple negative breast cancer (TNBC) patients with residual invasive disease after platinum and taxanes based neoadjuvant chemotherapy,{'This study will evaluate the efficacy and safety of antharcycline-based adjuvant chemotherapy compared with observation in triple negative breast cancer (TNBC) patients with residual invasive disease after platinum and taxanes based neoadjuvant chemotherapy'},{'NCT04437160'},NCT04437160
,1,,nsaids,FALSE,1,FALSE,FALSE,This study will investigate if there is a change in consumption of opioids before and after omission of NSAIDs.,"{'This study will investigate if there is a change in consumption of opioids before and after omission of NSAIDs.', 'The investigators will also compare the blood samples and see if there is signs of impaired renal and cardiac function in the group that was treated with NSAIDs.'}",{'NCT04448652'},NCT04448652
1,,,zz06,FALSE,1,FALSE,FALSE,"This is a Phase 1, Multicenter, Open-label study to assess the safety, tolerability and preliminary efficacy of ZZ06 in participants with all Adult Patients with Advanced EGFR-positive Solid Tumor Malignancies who are not able to have current standard anti-tumor therapies.","{'This is a Phase 1, Multicenter, Open-label study to assess the safety, tolerability and preliminary efficacy of ZZ06 in participants with all Adult Patients with Advanced EGFR-positive Solid Tumor Malignancies who are not able to have current standard anti-tumor therapies.', 'The purpose of this study is to determine the maximum tolerated dose (MTD) , to characterise the safety, pharmacokinetics (PK), immunogenicity, pharmacodynamics (PD) and anti-tumor activity of ZZ06 as a single agent in adult participants with advanced solid tumors', 'A Phase 1, Multicenter, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Evidence of Antitumor Activity of ZZ06 in Adult Patients With Advanced EGFR Positive Solid Tumor Malignancies.'}",{'NCT04412616'},NCT04412616
,,,shr2554,FALSE,1,FALSE,FALSE,"The primary objective of this study in phase Ⅰstage is to assess the safety, feasibility of EZH2 inhibitor SHR2554 in combination with anti-PD-L1/TGFβ antibody SHR1701 in advanced pretreated solid tumors and b-cell lymphomas.","{'The primary objective of this study in phase Ⅰstage is to assess the safety, feasibility of EZH2 inhibitor SHR2554 in combination with anti-PD-L1/TGFβ antibody SHR1701 in advanced pretreated solid tumors and b-cell lymphomas.', 'The phase Ⅱ stage of this study is to primarily evaluate the efficacy of SHR2554 plus SHR1701 and the epigenetic modulating effect of SHR2554'}",{'NCT04407741'},NCT04407741
1,,,64cu-sartate,FALSE,1,FALSE,FALSE,The primary purpose of this study is to examine the safety and potential effectiveness of a drug molecule called 64Cu-SARTATE as a potential new way to detect neuroendocrine cancers,{'The primary purpose of this study is to examine the safety and potential effectiveness of a drug molecule called 64Cu-SARTATE as a potential new way to detect neuroendocrine cancers'},{'NCT04440956'},NCT04440956
1,,,lutetium-177,FALSE,1,FALSE,FALSE,Radioligand therapy (RLT) using Lutetium-177 labelled PSMA is a promising new therapeutic approach to treat metastatic prostate cancer.,"{'Radioligand therapy (RLT) using Lutetium-177 labelled PSMA is a promising new therapeutic approach to treat metastatic prostate cancer.', 'In the last few years, several lutetium-177 (177Lu, β emitter) labeled PSMA ligands have been developed and are currently applied to treat metastatic castrate resistant prostate cancer patients.'}",{'NCT04443062'},NCT04443062
1,,,shr1701,FALSE,1,FALSE,FALSE,"The primary objective of this study in phase Ⅰstage is to assess the safety, feasibility of EZH2 inhibitor SHR2554 in combination with anti-PD-L1/TGFβ antibody SHR1701 in advanced pretreated solid tumors and b-cell lymphomas.","{'The primary objective of this study in phase Ⅰstage is to assess the safety, feasibility of EZH2 inhibitor SHR2554 in combination with anti-PD-L1/TGFβ antibody SHR1701 in advanced pretreated solid tumors and b-cell lymphomas.', 'The phase Ⅱ stage of this study is to primarily evaluate the efficacy of SHR2554 plus SHR1701 and the epigenetic modulating effect of SHR2554'}",{'NCT04407741'},NCT04407741
1,,,syha1807,FALSE,1,FALSE,FALSE,"A Phase I, Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics and Clinical Activity of SYHA1807 Given Orally in Subjects With Extensive-Stage Small Cell Lung Cancer.","{'A Phase I, Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics and Clinical Activity of SYHA1807 Given Orally in Subjects With Extensive-Stage Small Cell Lung Cancer.', 'This is a phase I, open-label, multi-center, non-randomized, 2-part first time inhuman (FTIH) study for SYHA1807.', 'Once RP2D is identified, an expansion cohort (Part 2) of up to 12~40 subjects will be enrolled to further evaluate the clinical activity and tolerability of SYHA1807 in subjects with extensive-stage Small Cell Lung Cancer (SCLC)', 'Part 1 is a dose escalation phase to determine the recommended phase 2 dose (RP2D) for SYHA1807 based on the safety, tolerability and pharmacokinetics (PK) profiles observed after oral administration of SYHA1807.'}",{'NCT04404543'},NCT04404543
,1,,rai,FALSE,1,FALSE,FALSE,"Surgery is the standard therapeutic approach for patients with differentiated thyroid carcinoma (DTC), followed by radioiodine (RAI) therapy if indicated.","{'Surgery is the standard therapeutic approach for patients with differentiated thyroid carcinoma (DTC), followed by radioiodine (RAI) therapy if indicated.', 'For women with DTC, the effects of RAI therapy on gonadal and reproductive function are an important consideration.', 'This study aimed to evaluate the effects of RAI therapy on ovarian function'}",{'NCT04396158'},NCT04396158
,1,,rt-155,FALSE,1,FALSE,FALSE,RT-155: Utilizing Pulsed Low-dose-rate (PLDR) Radiation to Prevent de Novo Stromal Activation; a Neoadjuvant Pancreatic Adenocarcinoma Phase I Trial.,{'RT-155: Utilizing Pulsed Low-dose-rate (PLDR) Radiation to Prevent de Novo Stromal Activation; a Neoadjuvant Pancreatic Adenocarcinoma Phase I Trial.'},{'NCT04452357'},NCT04452357
,,1,castrate,FALSE,1,FALSE,FALSE,"In the last few years, several lutetium-177 (177Lu, β emitter) labeled PSMA ligands have been developed and are currently applied to treat metastatic castrate resistant prostate cancer patients.","{'In the last few years, several lutetium-177 (177Lu, β emitter) labeled PSMA ligands have been developed and are currently applied to treat metastatic castrate resistant prostate cancer patients.'}",{'NCT04443062'},NCT04443062
1,,,gsk6097608,FALSE,1,FALSE,FALSE,"A Phase 1 First-Time-in-Human, Open-Label Study of GSK6097608 Administered as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors.","{'A Phase 1 First-Time-in-Human, Open-Label Study of GSK6097608 Administered as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors.', 'This first-time-in-human (FTIH) study will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of escalating doses of GSK6097608 given as monotherapy and in combination with dostarlimab in participants with advanced solid tumors.'}",{'NCT04446351'},NCT04446351
,1,,brf113928,FALSE,1,FALSE,FALSE,The general study design has been discussed and agreed with Chinese Health Authority and is applying a similar design used for global pivotal phase II study (BRF113928),{'The general study design has been discussed and agreed with Chinese Health Authority and is applying a similar design used for global pivotal phase II study (BRF113928)'},{'NCT04452877'},NCT04452877
,1,,citadel-,FALSE,1,FALSE,FALSE,"A Phase 2, Multicenter, Open-Label Study of Parsaclisib, a PI3Kδ Inhibitor, in Japanese Participants With Relapsed or Refractory Follicular Lymphoma (CITADEL-213).","{'A Phase 2, Multicenter, Open-Label Study of Parsaclisib, a PI3Kδ Inhibitor, in Japanese Participants With Relapsed or Refractory Follicular Lymphoma (CITADEL-213).'}",{'NCT04434937'},NCT04434937
1,,,tak-676,FALSE,1,FALSE,FALSE,The purpose of this study is to determine the safety and tolerability of TAK-676 administered as an SA or in combination with pembrolizumab in participants with advanced or metastatic solid tumors,"{'The purpose of this study is to determine the safety and tolerability of TAK-676 administered as an SA or in combination with pembrolizumab in participants with advanced or metastatic solid tumors', 'An Open-label, Dose Escalation, Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-676 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced or Metastatic Solid Tumors.'}",{'NCT04420884'},NCT04420884
,1,,tnt,FALSE,1,FALSE,FALSE,"While the use of TNT is increasingly common, prospective study of outcomes following TNT has been limited.","{'While the use of TNT is increasingly common, prospective study of outcomes following TNT has been limited.', 'More recently, TNT, comprised of neoadjuvant chemotherapy and chemoradiation followed by surgical resection, has been increasingly used as a standard therapy approach.', 'In this study, we will collect pre-treatment rectal adenocarcinoma specimens and determine clinical outcome, including pathologic complete response rate, post-treatment pathologic downstaging rate, recurrence-free survival (RFS), overall survival (OS) and neoadjuvant rectal score, among patients who are treated with standard neoadjuvant chemoradiation or TNT, with an aim to investigate how baseline biomarkers and changes in biomarkers with standard therapies may be associated with, and modulate, clinical outcomes'}",{'NCT04418895'},NCT04418895
1,,,triiodothyronine-thyroxine,FALSE,1,FALSE,FALSE,"The standard of care for rectal adenocarcinomas that are triiodothyronine-thyroxine (T3-T4) or node positive has generally been comprised of neoadjuvant chemoradiation, followed by surgical resection and then adjuvant chemotherapy.","{'The standard of care for rectal adenocarcinomas that are triiodothyronine-thyroxine (T3-T4) or node positive has generally been comprised of neoadjuvant chemoradiation, followed by surgical resection and then adjuvant chemotherapy.'}",{'NCT04418895'},NCT04418895
1,,,trs003,FALSE,1,FALSE,FALSE,1) to receive either TRS003 in combination with paclitaxel and carboplatin or China-approved bevacizumab in combination with paclitaxel and carboplatin for 4 to 6 cycles,"{'1) to receive either TRS003 in combination with paclitaxel and carboplatin or China-approved bevacizumab in combination with paclitaxel and carboplatin for 4 to 6 cycles', 'This is a double-blind Phase 3 clinical trial evaluating the efficacy and safety of TRS003 and paclitaxel-carboplatin versus China-approved bevacizumab and paclitaxel-carboplatin in patients with unresectable, locally advanced, or metastatic non-squamous non-small cell lung cancer (NSCLC).'}",{'NCT04416035'},NCT04416035
,,1,kasabach-merritt phenomenon,FALSE,1,FALSE,FALSE,A Clinical Study on the Treatment of Kaposiform Hemangioendothelioma (KHE) With Kasabach-Merritt Phenomenon (KMP) by Hormone Shock and Sirolimus Maintenance.,{'A Clinical Study on the Treatment of Kaposiform Hemangioendothelioma (KHE) With Kasabach-Merritt Phenomenon (KMP) by Hormone Shock and Sirolimus Maintenance.'},{'NCT04409691'},NCT04409691
,,1,kmp,FALSE,1,FALSE,FALSE,A Clinical Study on the Treatment of Kaposiform Hemangioendothelioma (KHE) With Kasabach-Merritt Phenomenon (KMP) by Hormone Shock and Sirolimus Maintenance.,{'A Clinical Study on the Treatment of Kaposiform Hemangioendothelioma (KHE) With Kasabach-Merritt Phenomenon (KMP) by Hormone Shock and Sirolimus Maintenance.'},{'NCT04409691'},NCT04409691
1,,,adp-a2m4,FALSE,1,FALSE,FALSE,A Phase 2 Pilot Study of ADP-A2M4 in Combination With Pembrolizumab in Subjects With Recurrent or Metastatic Head and Neck Cancer.,"{'A Phase 2 Pilot Study of ADP-A2M4 in Combination With Pembrolizumab in Subjects With Recurrent or Metastatic Head and Neck Cancer.', 'This is a study to investigate the efficacy and safety of ADP-A2M4 in combination with pembrolizumab in HLA-A*02 eligible and MAGE-A4 positive subjects with recurrent or metastatic Head and Neck cancer'}",{'NCT04408898'},NCT04408898
1,,,ivermectin,FALSE,1,FALSE,FALSE,Ivermectin plus losartan as prophilaxy to severe events in patients with cancer with recent diagnosis of COVID-19,"{'Ivermectin plus losartan as prophilaxy to severe events in patients with cancer with recent diagnosis of COVID-19', 'Randomized, Doubled-blind Phase II Trial Evaluating the Use of Ivermectin Plus Losartan for Prophylaxis of Severe Events in Cancer Patients With Recent Diagnosis of COVID-19.'}",{'NCT04447235'},NCT04447235
,1,,cabozaninib,FALSE,1,FALSE,FALSE,"Cabozaninib, a VEGF inhibitor, in combination with atezolizumab, an inhibitor of PD-L1, may be active in endocrine tumors by overcoming the resistance to prior antiangiogenic drugs.","{'Cabozaninib, a VEGF inhibitor, in combination with atezolizumab, an inhibitor of PD-L1, may be active in endocrine tumors by overcoming the resistance to prior antiangiogenic drugs.'}",{'NCT04400474'},NCT04400474
1,,,ro7297089,FALSE,1,FALSE,FALSE,"An Open-Label, Multicenter, Phase I Trial Evaluating The Safety And Pharmacokinetics Of Escalating Doses Of RO7297089 In Patients With Relapsed Or Refractory Multiple Myeloma.","{'An Open-Label, Multicenter, Phase I Trial Evaluating The Safety And Pharmacokinetics Of Escalating Doses Of RO7297089 In Patients With Relapsed Or Refractory Multiple Myeloma.', 'This is a first-in-human Phase I, open-label, multicenter, global, dose-escalation study designed to evaluate the safety, tolerability, and pharmacokinetics of RO7297089 and make a preliminary assessment of anti-tumor activity in patients with R/R MM for whom no established therapy for MM is appropriate and available or who are intolerant to those established therapies'}",{'NCT04434469'},NCT04434469
,,1,subprotocol g,FALSE,1,FALSE,FALSE,MATCH Treatment Subprotocol G: Phase II Study of Crizotinib in Patients With ROS1 Translocations (Other Than Patients With Non-Small Cell Lung Cancer).,{'MATCH Treatment Subprotocol G: Phase II Study of Crizotinib in Patients With ROS1 Translocations (Other Than Patients With Non-Small Cell Lung Cancer).'},{'NCT04439253'},NCT04439253
,1,,descartes-11 consolidation,FALSE,1,FALSE,FALSE,Descartes-11 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy.,{'Descartes-11 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy.'},{'NCT04436029'},NCT04436029
1,,,descartes-11,FALSE,1,FALSE,FALSE,To assess Minimal Residual Disease (MRD)-negative Complete Response (sCR) rate after consolidation treatment with Descartes-11 in patients with high-risk myeloma who have residual disease following induction therapy,{'To assess Minimal Residual Disease (MRD)-negative Complete Response (sCR) rate after consolidation treatment with Descartes-11 in patients with high-risk myeloma who have residual disease following induction therapy'},{'NCT04436029'},NCT04436029
,1,,lola,FALSE,1,FALSE,FALSE,The LOLA Trial.,{'The LOLA Trial.'},{'NCT04427787'},NCT04427787
1,,,sar442720,FALSE,1,FALSE,FALSE,- To characterize the safety and tolerability of SAR442720 in combination with pembrolizumab in patients with advanced solid tumors including NSCLC who progressed on anti-PD-1/PD L1 containing therapy and advanced colorectal cancer (CRC) after progression to all standard of care (SOC) therapy - To define the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) for the combination of SAR442720 and pembrolizumab in patients with solid tumors Secondary Objectives: - To document the pharmacokinetic (PK) of SAR442720 in combination with pembrolizumab and to document the PK of pembrolizumab in combination with SAR442720 - To estimate the anti-tumor effects of SAR442720 in combination with pembrolizumab in all participants,"{'- To characterize the safety and tolerability of SAR442720 in combination with pembrolizumab in patients with advanced solid tumors including NSCLC who progressed on anti-PD-1/PD L1 containing therapy and advanced colorectal cancer (CRC) after progression to all standard of care (SOC) therapy - To define the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) for the combination of SAR442720 and pembrolizumab in patients with solid tumors Secondary Objectives: - To document the pharmacokinetic (PK) of SAR442720 in combination with pembrolizumab and to document the PK of pembrolizumab in combination with SAR442720 - To estimate the anti-tumor effects of SAR442720 in combination with pembrolizumab in all participants', 'A Phase 1, Open-label, Multicenter, Safety Study of SAR442720 in Combination With Pembrolizumab in Patients With Advanced Malignancies.'}",{'NCT04418661'},NCT04418661
,1,,citrate,FALSE,1,FALSE,FALSE,"The use of plasma as a substitution fluid further increases treatment costs and is associated with risk of infections, allergic reactions and citrate-induced hypocalcemia.","{'The use of plasma as a substitution fluid further increases treatment costs and is associated with risk of infections, allergic reactions and citrate-induced hypocalcemia.'}",{'NCT04418531'},NCT04418531
,,1,dfpp,FALSE,1,FALSE,FALSE,Measurement of the antibody titer in treated patient and recovered fluid showed that antibody removal was extremely effective and that large part of antibodies was removed during the first DFPP procedure.,"{'Measurement of the antibody titer in treated patient and recovered fluid showed that antibody removal was extremely effective and that large part of antibodies was removed during the first DFPP procedure.', 'Thus, in this novel pilot study we aim to explore whether the infusion of antibodies obtained with one single DFPP procedure from voluntary convalescent donors could offer an effective and safe therapeutic option for patients with earlier stages of coronavirus (COVID-19) pneumonia requiring oxygen supply without mechanical ventilation'}",{'NCT04418531'},NCT04418531
1,,,auto1,FALSE,1,FALSE,FALSE,"An Open-Label, Multi-Centre, Phase Ib/II Study Evaluating the Safety and Efficacy of AUTO1, a CAR T Cell Treatment Targeting CD19, in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia.","{'An Open-Label, Multi-Centre, Phase Ib/II Study Evaluating the Safety and Efficacy of AUTO1, a CAR T Cell Treatment Targeting CD19, in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia.'}",{'NCT04404660'},NCT04404660
1,,,can04,FALSE,1,FALSE,FALSE,Both CAN04 and pembrolizumab will be administered intravenously,"{'Both CAN04 and pembrolizumab will be administered intravenously', 'The study aims to establish a recommended dose of CAN04 in combination with the standard dose of pembrolizumab.', 'An Open-label, Safety and Tolerability Phase 1b Trial of CAN04, a Fully Humanized Anti-IL1RAP Monoclonal Antibody, in Combination With Pembrolizumab in Subjects With Solid Tumors Progressing on PD-1/PD-L1 Inhibitor-containing Regimens.'}",{'NCT04452214'},NCT04452214
,1,,hva,FALSE,1,FALSE,FALSE,Efficacy and Safety of HVA Regimens as Salvage Treatment in Relapsed/Refractory (rr) Acute Myeloid Leukemia (AML).,{'Efficacy and Safety of HVA Regimens as Salvage Treatment in Relapsed/Refractory (rr) Acute Myeloid Leukemia (AML).'},{'NCT04424147'},NCT04424147
1,,,epidiolex,FALSE,1,FALSE,FALSE,The purpose of this phase I/Ib study is to determine the safety profile of Epidiolex (CBD oil) in biochemically recurrent prostate cancer patients.,"{'The purpose of this phase I/Ib study is to determine the safety profile of Epidiolex (CBD oil) in biochemically recurrent prostate cancer patients.', 'A Phase I/Ib Study on the Safety of Epidiolex in Patients With Prostate Cancer With Rising PSA After Localized Therapy With Either Surgery or Radiation.'}",{'NCT04428203'},NCT04428203
1,,,gq1001,FALSE,1,FALSE,FALSE,"A Phase 1, First-In-Human, Multicenter, Open-Label, Study of GQ1001, a HER2 Targeted Antibody-Drug Conjugate, Administered Intravenously, in Adult Patients With HER2-Positive Advanced Solid Tumors.","{'A Phase 1, First-In-Human, Multicenter, Open-Label, Study of GQ1001, a HER2 Targeted Antibody-Drug Conjugate, Administered Intravenously, in Adult Patients With HER2-Positive Advanced Solid Tumors.', 'Phase I Dose Finding Study for GQ1001 in Patients with HER2-Positive Advanced Solid Tumors'}",{'NCT04450732'},NCT04450732
1,,,bca101,FALSE,1,FALSE,FALSE,"The investigational drug to be studied in this protocol, BCA101, is a first-in-class compound that combines EGFR with TGFβ.","{'The investigational drug to be studied in this protocol, BCA101, is a first-in-class compound that combines EGFR with TGFβ.'}",{'NCT04429542'},NCT04429542
1,,,au-011,FALSE,1,FALSE,FALSE,The primary objective is to assess safety and efficacy of AU-011 via suprachoroidal injection to treat primary indeterminate lesions and small choroidal melanoma,"{'The primary objective is to assess safety and efficacy of AU-011 via suprachoroidal injection to treat primary indeterminate lesions and small choroidal melanoma', 'A Phase 2 Trial of AU-011 Via Suprachoroidal Administration With a Dose Escalation Phase (Open-label, Ascending Single and Repeat Dose) and a Randomized, Masked Dose Expansion Phase Designed to Evaluate the Safety and Efficacy of AU-011 in Subjects With Primary Indeterminate Lesions and Small Choroidal Melanoma.'}",{'NCT04417530'},NCT04417530
,1,,lerotinib,FALSE,1,FALSE,FALSE,Lerotinib Versus Investigator's Choice Single-agent Chemotherapy in Patients With Locally Advanced/Metastatic Esophageal Squamous Cell Carcinoma and EGFR Overexpression That Progressed After Second-line Therapy:Phase 3 Study.,"{""Lerotinib Versus Investigator's Choice Single-agent Chemotherapy in Patients With Locally Advanced/Metastatic Esophageal Squamous Cell Carcinoma and EGFR Overexpression That Progressed After Second-line Therapy:Phase 3 Study.""}",{'NCT04415853'},NCT04415853
1,,,larotinib,FALSE,1,FALSE,FALSE,",who received Larotinib and the chemotherapy regimen chosen by the investigator (Irinotecan Hydrochloride Injection or Tegafur Gimeracil Oteracil Potassium Capsule),respecitively.","{',who received Larotinib and the chemotherapy regimen chosen by the investigator (Irinotecan Hydrochloride Injection or Tegafur Gimeracil Oteracil Potassium Capsule),respecitively.'}",{'NCT04415853'},NCT04415853
1,,,vs-6063,FALSE,1,FALSE,FALSE,This phase II MATCH treatment trial identifies the effects of VS-6063 (defactinib) in patients whose cancer has a genetic change called NF2 mutation.,"{'This phase II MATCH treatment trial identifies the effects of VS-6063 (defactinib) in patients whose cancer has a genetic change called NF2 mutation.', 'MATCH Treatment Subprotocol U: VS-6063 (Defactinib) in Patients With Tumors With NF2 Loss.'}",{'NCT04439331'},NCT04439331
,1,,f-arag,FALSE,1,FALSE,FALSE,The main goal of the PET/CT scan with 18F]F-AraG is to evaluate how [18F]F-AraG uptake changes before and after administration of either nivolumab or nivolumab/CMP-001 combination,{'The main goal of the PET/CT scan with 18F]F-AraG is to evaluate how [18F]F-AraG uptake changes before and after administration of either nivolumab or nivolumab/CMP-001 combination'},{'NCT04401995'},NCT04401995
1,,,asn-002,FALSE,1,FALSE,FALSE,1) Evaluate the efficacy of intralesional ASN-002 in non-target tumours when administered in combination with oral vismodegib in patients with BCCs.,"{'1) Evaluate the efficacy of intralesional ASN-002 in non-target tumours when administered in combination with oral vismodegib in patients with BCCs.', '2. Evaluate the efficacy of intralesional ASN-002 in target tumours when administered in combination with oral vismodegib in patients with BCCs.', '1. Evaluate the safety and tolerability of intralesional ASN-002 when administered in combination with oral vismodegib in patients with Basal Cell Carcinomas (BCC)s;', 'A Phase 2A Study to Assess the Safety and Efficacy of ASN-002 Combined With a Hedgehog Pathway Inhibitor in the Treatment of Multiple Low Risk Basal Cell Carcinomas in Sporadic or Basal Cell Nevus Syndrome Patients.'}",{'NCT04416516'},NCT04416516
1,,,nc410,FALSE,1,FALSE,FALSE,"A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of NC410 in Subjects With Advanced or Metastatic Solid Tumors.","{'A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of NC410 in Subjects With Advanced or Metastatic Solid Tumors.', 'This research study is studying a new drug, NC410, as a possible treatment for advanced or metastatic solid tumors'}",{'NCT04408599'},NCT04408599
1,,,tq-b3525,FALSE,1,FALSE,FALSE,"A Single-arm, Multicenter Phase II Clinical Trial of TQ-B3525 Tablet in the Treatment of Relapsed / Refractory Mantle Cell Lymphoma (MCL).","{'A Single-arm, Multicenter Phase II Clinical Trial of TQ-B3525 Tablet in the Treatment of Relapsed / Refractory Mantle Cell Lymphoma (MCL).', 'This is a study to evaluate the safety and efficacy of TQ-B3525 tablets in patients with relapsed / refractory mantle cell lymphoma (MCL)'}",{'NCT04398953'},NCT04398953
1,,,dm1,FALSE,1,FALSE,FALSE,"Ado-trastuzumab emtansine is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug called DM1.","{'Ado-trastuzumab emtansine is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug called DM1.'}",{'NCT04439110'},NCT04439110
1,,,bacillus-calmette-guerin,FALSE,1,FALSE,FALSE,A Phase 3 Study of CG0070 in Patients With Non-Muscular Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus-Calmette-Guerin (BCG).,{'A Phase 3 Study of CG0070 in Patients With Non-Muscular Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus-Calmette-Guerin (BCG).'},{'NCT04452591'},NCT04452591
,1,,subprotocol b,FALSE,1,FALSE,FALSE,MATCH Treatment Subprotocol B: Phase II Study of Afatinib in Patients With Tumors With HER2 Activating Mutations.,{'MATCH Treatment Subprotocol B: Phase II Study of Afatinib in Patients With Tumors With HER2 Activating Mutations.'},{'NCT04439136'},NCT04439136
1,,,epi-7386,FALSE,1,FALSE,FALSE,- The effect of EPI-7386 on certain substances in the body.,"{'- The effect of EPI-7386 on certain substances in the body.', 'Therefore, the main purpose of this study is to assess the safety (side effects) of EPI-7386 and to find a dose that can be given without unacceptable side effects.', 'All patients in the study will receive EPI-7386.', '- The effect of EPI-7386 on prostate cancer.', 'Since this is the first study of EPI-7386 in humans, there is no information about how it affects people or what dose should be used.', '- The possibility that EPI-7386 can interact with other drugs', 'This is a phase I, clinical research study of EPI-7386, an investigational drug being studied as a treatment for patients with prostate cancer.', '- How the amount of EPI-7386 in the blood changes over time.', 'A Phase 1, Open-label Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral EPI-7386 in Patients With Metastatic Castration-Resistant Prostate Cancer.'}",{'NCT04421222'},NCT04421222
1,,,4scar-t,FALSE,1,FALSE,FALSE,4SCAR-T Therapy After Anti-CD19 Immunotherapy Targeting B Cell Acute Lymphoblastic Leukemia.,{'4SCAR-T Therapy After Anti-CD19 Immunotherapy Targeting B Cell Acute Lymphoblastic Leukemia.'},{'NCT04430530'},NCT04430530
,1,,faza,FALSE,1,FALSE,FALSE,PET scans may be used to check the amounts of oxygen within areas of cancer with a special radioactive tracer called FAZA that specifically looks for areas of low oxygen.,{'PET scans may be used to check the amounts of oxygen within areas of cancer with a special radioactive tracer called FAZA that specifically looks for areas of low oxygen.'},{'NCT04409314'},NCT04409314
1,,,fezolinetant,TRUE,1,FALSE,FALSE,The study treatment is fezolinetant (1 tablet of fezolinetant) once a day.,"{'The study treatment is fezolinetant (1 tablet of fezolinetant) once a day.', 'The purpose of this study is to find out how safe it is for these women to take fezolinetant long term (up to 52 weeks).'}",{'NCT04451226'},NCT04451226
1,,,fezolinetant,FALSE,1,FALSE,FALSE,A Single-Arm Phase 3 Clinical Study to Investigate the Long-Term Safety of Fezolinetant in Women in China Suffering From Vasomotor Symptoms (Hot Flashes) Associated With Menopause.,"{'A Single-Arm Phase 3 Clinical Study to Investigate the Long-Term Safety of Fezolinetant in Women in China Suffering From Vasomotor Symptoms (Hot Flashes) Associated With Menopause.', 'The study treatment is fezolinetant (1 tablet of fezolinetant) once a day.'}",{'NCT04451226'},NCT04451226
1,,,triprilimab,FALSE,1,TRUE,FALSE,"A Single-arm, Open Multicenter Phase II Clinical Study of Triprilimab(JS001) and Chemotherapy Combined With Local Treatment for Multiple Metastatic NPC.","{'A Single-arm, Open Multicenter Phase II Clinical Study of Triprilimab(JS001) and Chemotherapy Combined With Local Treatment for Multiple Metastatic NPC.'}",{'NCT04421469'},NCT04421469
1,,,cn1,FALSE,1,FALSE,FALSE,"A Phase I, Open Label, Multi-Center, Dose Escalation Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of CN1 in Patients With Advanced Solid Tumors or B-cell Lymphoma.","{'A Phase I, Open Label, Multi-Center, Dose Escalation Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of CN1 in Patients With Advanced Solid Tumors or B-cell Lymphoma.', 'This study is the first-in-human clinical trial of CN1 to evaluate the safety, tolerability, pharmacokinetic (PK) profile and preliminary efficacy of CN1 in patients with advanced solid tumors or B-cell lymphoma.'}",{'NCT04418141'},NCT04418141
1,,,bezlotoxumab,FALSE,1,TRUE,FALSE,Investigation of efficacy and tolerability of bezlotoxumab in patients with cancer diagnosis in terms of preventing CDI recurrence,"{'Investigation of efficacy and tolerability of bezlotoxumab in patients with cancer diagnosis in terms of preventing CDI recurrence', 'Is Bezlotoxumab Effective, Tolerable and Cost Saving in Preventing Recurrent Clostridium Difficile Infections in Patients With Malignancies?'}",{'NCT04415918'},NCT04415918
1,,,shr-1802,FALSE,1,FALSE,FALSE,This is the first study to test SHR-1802 in humans.,"{'This is the first study to test SHR-1802 in humans.', 'The primary purpose of this study is to see if SHR-1802 is safe and tolerable for patients with locally advanced/unresectable or metastatic malignancies that are refractory to available therapy or for which no standard therapy is available', 'Tolerability, Safety and Pharmacokinetic Characteristics of SHR-1802 in Patients With Advanced Malignancy: a Phase I Clinical Study.'}",{'NCT04414150'},NCT04414150
1,,,peg-endo,FALSE,1,FALSE,FALSE,"A Phase Ⅰb Study Evaluating the Safety, Tolerability and Pharmacokinetics of Pegylated Recombinant Human Endostatin (PEG-ENDO) in Subjects With Advanced / Metastatic Non-small Cell Lung Cancer (NSCLC) or Other Solid Tumors.","{'A Phase Ⅰb Study Evaluating the Safety, Tolerability and Pharmacokinetics of Pegylated Recombinant Human Endostatin (PEG-ENDO) in Subjects With Advanced / Metastatic Non-small Cell Lung Cancer (NSCLC) or Other Solid Tumors.', 'The primary purpose of this study is to examine the safety, tolerability and pharmacokinetics of PEG-ENDO in combination with docetaxel in subjects previously treated or untreated (standard therapy is not suitable or without standard therapy) for advanced or metatatic non-small cell lung cancer (NSCLC) or other solid tumors'}",{'NCT04413227'},NCT04413227
1,,,ab011,FALSE,1,FALSE,FALSE,"This is an open, two-stage, phase I study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of AB011 injection in patients with CLDN18.2-positive advanced solid tumors","{'This is an open, two-stage, phase I study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of AB011 injection in patients with CLDN18.2-positive advanced solid tumors', 'An Open, Two-stage, Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AB011 Injection in Patients With CLDN18.2-positive Advanced Solid Tumors.'}",{'NCT04400383'},NCT04400383
,,1,lelc,FALSE,1,FALSE,FALSE,"Although target antibody drugs for PD-1 and PD-L1 have achieved good results in immunotherapy of many malignant tumors, there is still a lack of corresponding clinical research reports on whether LELC treatment can benefit.","{'Although target antibody drugs for PD-1 and PD-L1 have achieved good results in immunotherapy of many malignant tumors, there is still a lack of corresponding clinical research reports on whether LELC treatment can benefit.'}",{'NCT04430166'},NCT04430166
1,,,inv-1120,FALSE,1,FALSE,FALSE,"Phase 1, first-in-human, open-label dose-escalation study to determine the MTD and RP2D, and to assess the DLT of INV-1120 (also referred to as investigational product or IP).","{'Phase 1, first-in-human, open-label dose-escalation study to determine the MTD and RP2D, and to assess the DLT of INV-1120 (also referred to as investigational product or IP).', 'The safety, tolerability, and PK of INV-1120 will be assessed in adult patients with advanced solid tumors.', 'A Phase 1, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Evidence of Antitumor Activity of INV-1120 as a Single Agent in Adult Patients With Advanced Solid Tumors.'}",{'NCT04443088'},NCT04443088
,1,,lynk-003,FALSE,1,FALSE,FALSE,Compared to Bevacizumab With 5-FU in Participants With Unresectable or Metastatic Colorectal Cancer Who Have Not Progressed Following First-line Induction of FOLFOX With Bevacizumab (LYNK-003).,{'Compared to Bevacizumab With 5-FU in Participants With Unresectable or Metastatic Colorectal Cancer Who Have Not Progressed Following First-line Induction of FOLFOX With Bevacizumab (LYNK-003).'},{'NCT04456699'},NCT04456699
1,,,triprilumab,FALSE,1,TRUE,FALSE,This study is designed to observe and evaluate the safety and the efficacy of the anti-programmed-death-1 antibody (anti-PD-1) Triprilumab in combination with chemotherapy of Gemcitabine PLUS Cisplatin in patients who were advanced intrahepatic cholangiocarcinoma with no chance for primary surgery,{'This study is designed to observe and evaluate the safety and the efficacy of the anti-programmed-death-1 antibody (anti-PD-1) Triprilumab in combination with chemotherapy of Gemcitabine PLUS Cisplatin in patients who were advanced intrahepatic cholangiocarcinoma with no chance for primary surgery'},{'NCT04413734'},NCT04413734
1,,,swi019,FALSE,1,FALSE,FALSE,The study will also assess the pharmacokinetics and pharmacodynamics of CLBR001 + SWI019,"{'The study will also assess the pharmacokinetics and pharmacodynamics of CLBR001 + SWI019', 'A Phase 1, Open-label, Dose Escalating Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the Combination of CLBR001 and SWI019 in Patients With Relapsed/Refractory B-cell Malignancies.', 'This first-in-human study will assess the safety and tolerability of CLBR001 + SWI019 and is designed to determine the maximum tolerated dose (MTD) or optimal SWI019 dose (OSD).', 'Patients will be administered a single infusion of CLBR001 cells followed by cycles of SWI019.'}",{'NCT04450069'},NCT04450069
1,,,tqb3473,FALSE,1,FALSE,FALSE,"This is a study to evaluate the maximum tolerated dose (MTD), occurrence of all adverse events (AE) and serious adverse events (SAE) , pharmacokinetic parameters and antitumor effect of TQB3473 tablets in Chinese adult patients with Relapsed or refractory hematological malignancies","{'This is a study to evaluate the maximum tolerated dose (MTD), occurrence of all adverse events (AE) and serious adverse events (SAE) , pharmacokinetic parameters and antitumor effect of TQB3473 tablets in Chinese adult patients with Relapsed or refractory hematological malignancies', 'A Phase I, Open-label, Dose Escalation and Expansion Study to Evaluate the Tolerance, Efficacy and Pharmacokinetics of TQB3473 Tablets.'}",{'NCT04412577'},NCT04412577
,1,,ar2,FALSE,1,FALSE,FALSE,"A Phase II Study of Acalabrutinib, Lenalidomide, and Rituximab (aR2) in Patients With Previously Untreated Follicular Lymphoma.","{'A Phase II Study of Acalabrutinib, Lenalidomide, and Rituximab (aR2) in Patients With Previously Untreated Follicular Lymphoma.'}",{'NCT04404088'},NCT04404088
,1,,lopinavir/ritonavir,FALSE,1,FALSE,FALSE,This phase II trial studies how well lopinavir/ritonavir works in treating COVID-19 positive patients with cancer and a weakened immune system (immune-suppression) in the last year and have mild or moderate symptoms caused by COVID-19.,"{'This phase II trial studies how well lopinavir/ritonavir works in treating COVID-19 positive patients with cancer and a weakened immune system (immune-suppression) in the last year and have mild or moderate symptoms caused by COVID-19.', 'A Double-Blind, Randomized, Placebo-Controlled Phase II Study of Lopinavir/Ritonavir Versus Placebo in COVID-19 Positive Patients With Cancer and Immune Suppression in the Last Year.', 'Lopinavir/ritonavir may help to lessen or prevent COVID-19 symptoms from getting worse in cancer patients'}",{'NCT04455958'},NCT04455958
,,1,covid-19,FALSE,1,FALSE,FALSE,This phase II trial studies how well lopinavir/ritonavir works in treating COVID-19 positive patients with cancer and a weakened immune system (immune-suppression) in the last year and have mild or moderate symptoms caused by COVID-19.,{'This phase II trial studies how well lopinavir/ritonavir works in treating COVID-19 positive patients with cancer and a weakened immune system (immune-suppression) in the last year and have mild or moderate symptoms caused by COVID-19.'},{'NCT04455958'},NCT04455958
,1,,tpm,FALSE,1,FALSE,FALSE,"The investigators used TPM regimen (thalidomide + prednison + methotrexate ) to treat LGLL since 2013, and 18/20 patients (90%) obtained clinical response, including 80% complete response.","{'The investigators used TPM regimen (thalidomide + prednison + methotrexate ) to treat LGLL since 2013, and 18/20 patients (90%) obtained clinical response, including 80% complete response.', 'Therefore, the investigators designed this multicenter clinical trial to validate the efficacy of the TPM regimen in symptomatic T-LGLL and CLPD-NK'}",{'NCT04453345'},NCT04453345
1,,,bi 764532,FALSE,1,FALSE,FALSE,To determine the maximum tolerated dose(s) (MTD) or the Recommended Dose for Expansion (RDE) and dosing regimen for further development of BI 764532.,"{'To determine the maximum tolerated dose(s) (MTD) or the Recommended Dose for Expansion (RDE) and dosing regimen for further development of BI 764532.', 'Additional objectives are to document the safety and tolerability of BI 764532, to characterise pharmacokinetics and pharmacodynamics, and to evaluate efficacy signals.', 'A First -in Human Phase I, Non-randomized, Open-label, Multi-center Dose Escalation Trial of BI 764532 Administered by Repeated Intravenous Infusions in Patients With Small Cell Lung Carcinoma and Other Neuroendocrine Neoplasms Expressing DLL3.', 'Phase Ib will further explore BI 764532 in selected patients populations based on data from phase Ia. The Phase Ib objectives, endpoints and design will be specified in a study protocol amendment after availability of phase Ia results'}",{'NCT04429087'},NCT04429087
,1,,carilizumab,FALSE,1,TRUE,FALSE,"A Single-arm, Open, Prospective, Single-center, Phase Ⅱ Clinical Study of Carilizumab Combined With Apatinib in theTtreatment of Advanced Inoperable Resection of Undifferentiated Pleomorphic Sarcoma and Alveolar Soft Tissue Sarcoma.","{'A Single-arm, Open, Prospective, Single-center, Phase Ⅱ Clinical Study of Carilizumab Combined With Apatinib in theTtreatment of Advanced Inoperable Resection of Undifferentiated Pleomorphic Sarcoma and Alveolar Soft Tissue Sarcoma.'}",{'NCT04447274'},NCT04447274
1,,,enol-oxaloacetate,FALSE,1,FALSE,FALSE,"A Phase 2, Randomized, Open-Label Study of Anhydrous Enol-Oxaloacetate in Subjects With Newly Diagnosed Glioblastoma Multiforme.","{'A Phase 2, Randomized, Open-Label Study of Anhydrous Enol-Oxaloacetate in Subjects With Newly Diagnosed Glioblastoma Multiforme.', 'This study is testing adjuvant Anhydrous Enol-Oxaloacetate (AEO) in GBM, an orally active drug candidate which in animal studies has demonstrated decreased tumor growth rate and increased survival', 'Treatment with Anhydrous Enol-Oxaloacetate will be added to the Standard of Care.'}",{'NCT04450160'},NCT04450160
,1,,anhydrous,FALSE,1,FALSE,FALSE,"A Phase 2, Randomized, Open-Label Study of Anhydrous Enol-Oxaloacetate in Subjects With Newly Diagnosed Glioblastoma Multiforme.","{'A Phase 2, Randomized, Open-Label Study of Anhydrous Enol-Oxaloacetate in Subjects With Newly Diagnosed Glioblastoma Multiforme.'}",{'NCT04450160'},NCT04450160
,1,,anhydrous,TRUE,1,FALSE,FALSE,"This study is testing adjuvant Anhydrous Enol-Oxaloacetate (AEO) in GBM, an orally active drug candidate which in animal studies has demonstrated decreased tumor growth rate and increased survival","{'This study is testing adjuvant Anhydrous Enol-Oxaloacetate (AEO) in GBM, an orally active drug candidate which in animal studies has demonstrated decreased tumor growth rate and increased survival'}",{'NCT04450160'},NCT04450160
1,,,aeo,FALSE,1,FALSE,FALSE,"This study is testing adjuvant Anhydrous Enol-Oxaloacetate (AEO) in GBM, an orally active drug candidate which in animal studies has demonstrated decreased tumor growth rate and increased survival","{'This study is testing adjuvant Anhydrous Enol-Oxaloacetate (AEO) in GBM, an orally active drug candidate which in animal studies has demonstrated decreased tumor growth rate and increased survival'}",{'NCT04450160'},NCT04450160
1,,,clbr001,FALSE,1,FALSE,FALSE,The study will also assess the pharmacokinetics and pharmacodynamics of CLBR001 + SWI019,"{'The study will also assess the pharmacokinetics and pharmacodynamics of CLBR001 + SWI019', 'A Phase 1, Open-label, Dose Escalating Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the Combination of CLBR001 and SWI019 in Patients With Relapsed/Refractory B-cell Malignancies.'}",{'NCT04450069'},NCT04450069
1,,,ab-106,FALSE,1,FALSE,FALSE,"The purpose of the study is to evaluate safety, pharmacokinetics and efficacy of AB-106 monotherapy in the treatment of advanced NSCLC","{'The purpose of the study is to evaluate safety, pharmacokinetics and efficacy of AB-106 monotherapy in the treatment of advanced NSCLC', 'A Multicenter, Open Label, Single Arm Phase 2 Study of AB-106 in the Treatment of Locally Advanced and Metastatic NSCLC.'}",{'NCT04395677'},NCT04395677
1,,,ctx130,FALSE,1,FALSE,FALSE,"This is a single-arm, open-label, multicenter, Phase 1 study evaluating the safety and efficacy of CTX130 in subjects with relapsed or refractory renal cell carcinoma","{'This is a single-arm, open-label, multicenter, Phase 1 study evaluating the safety and efficacy of CTX130 in subjects with relapsed or refractory renal cell carcinoma'}",{'NCT04438083'},NCT04438083
,1,,donafinib,FALSE,1,FALSE,FALSE,Here investigators intend to explore the safety and efficacy of Donafinib Combined With Anti-PD-1 Antibody as postoperative adjuvant therapy for HCC patients with high risks of recurrence,"{'Here investigators intend to explore the safety and efficacy of Donafinib Combined With Anti-PD-1 Antibody as postoperative adjuvant therapy for HCC patients with high risks of recurrence', 'A Study on the Safety and Efficacy of Donafinib Combined With Anti-PD-1 Antibody as Adjuvant Therapy for HCC Patients With High Risks of Recurrence.'}",{'NCT04418401'},NCT04418401
1,,,ql1604,FALSE,1,FALSE,FALSE,A Study of QL1604 Plus Nab-paclitaxel Versus Paclitaxel for Participants With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma That Progressed After Therapy With Platinum and Fluoropyrimidine.,{'A Study of QL1604 Plus Nab-paclitaxel Versus Paclitaxel for Participants With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma That Progressed After Therapy With Platinum and Fluoropyrimidine.'},{'NCT04435652'},NCT04435652
,1,,carrelizumab,FALSE,1,TRUE,FALSE,The purpose of this study was to evaluate the efficacy and safety of carrelizumab combined with apatinib mesylate and standard chemotherapy (pemetrexed plus carboplatin) in patients with advanced non-squamous and non-small cell lung cancer who have failed tyrosine kinase inhibitor therapy and are ALK-positive,{'The purpose of this study was to evaluate the efficacy and safety of carrelizumab combined with apatinib mesylate and standard chemotherapy (pemetrexed plus carboplatin) in patients with advanced non-squamous and non-small cell lung cancer who have failed tyrosine kinase inhibitor therapy and are ALK-positive'},{'NCT04425135'},NCT04425135
,1,,pemetrixed,FALSE,1,FALSE,FALSE,Phase II Single-arm Clinical Study of Camrelizumab Combined With Apatinib Mesylate and Standard Chemotherapy (Pemetrixed +Carboplatin) in Patients With Tyrosine Kinase Inhibitor Failure in ALK-positive Advanced NSCLC.,{'Phase II Single-arm Clinical Study of Camrelizumab Combined With Apatinib Mesylate and Standard Chemotherapy (Pemetrixed +Carboplatin) in Patients With Tyrosine Kinase Inhibitor Failure in ALK-positive Advanced NSCLC.'},{'NCT04425135'},NCT04425135
,1,,platin,FALSE,1,FALSE,FALSE,Those who progressed under osimertinib or under afatinib without T790M mutation will be treated according to the current treatment guidelines with Investigator´s choice of active therapy (ICT) including but not limited to platin doublet chemotherapy,{'Those who progressed under osimertinib or under afatinib without T790M mutation will be treated according to the current treatment guidelines with Investigator´s choice of active therapy (ICT) including but not limited to platin doublet chemotherapy'},{'NCT04413201'},NCT04413201
,1,,pisoxo,FALSE,1,FALSE,FALSE,Neoadjuvant Chemotherapy With Pressurized Intra Peritoneal Aerosol Chemotherapy(PIPAC) Plus SOX Plus Olaparib (PISOXO) for Locally-invaded-gastric Cancer (LIGC).,{'Neoadjuvant Chemotherapy With Pressurized Intra Peritoneal Aerosol Chemotherapy(PIPAC) Plus SOX Plus Olaparib (PISOXO) for Locally-invaded-gastric Cancer (LIGC).'},{'NCT04410887'},NCT04410887
,1,,pipac,FALSE,1,FALSE,FALSE,The main purpose of this study is to compare the safety and efficacy of PIPAC+SOX+OLAPARIB for locally-invaded-gastric cancer (LIGC) patients in China.,{'The main purpose of this study is to compare the safety and efficacy of PIPAC+SOX+OLAPARIB for locally-invaded-gastric cancer (LIGC) patients in China.'},{'NCT04410887'},NCT04410887
1,,,x-396,FALSE,1,FALSE,FALSE,"To assess efficacy and safety of oral X-396 (Ensartinib) capsule in Chinese ALK-positive NSCLC patients with brain metastases, eligible patients will be enrolled with objective responses being primary outcome measures","{'To assess efficacy and safety of oral X-396 (Ensartinib) capsule in Chinese ALK-positive NSCLC patients with brain metastases, eligible patients will be enrolled with objective responses being primary outcome measures', 'Efficacy and Safety of X-396 (Ensartinib) in ALK-Positive NSCLC Patients With Brain Metastases: A Phase Ⅱ, Open-Label, Single Arm, Multicenter Study.'}",{'NCT04415320'},NCT04415320
1,,,cc-98633,FALSE,1,FALSE,FALSE,"The dose-escalation part (Part A) of the study is to evaluate the safety and tolerability of increasing dose levels of CC-98633 to establish a recommended Phase 2 dose (RP2D); and the dose-expansion part (Part B) of the study is to further evaluate the safety, pharmacokinetics/pharmacodynamics, and efficacy of CC-98633 at the RP2D","{'The dose-escalation part (Part A) of the study is to evaluate the safety and tolerability of increasing dose levels of CC-98633 to establish a recommended Phase 2 dose (RP2D); and the dose-expansion part (Part B) of the study is to further evaluate the safety, pharmacokinetics/pharmacodynamics, and efficacy of CC-98633 at the RP2D', 'A Phase I, Multi Center, Open Label Study of CC-98633, BCMA Targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed and/or Refractory Multiple Myeloma.', 'This is a Phase 1, multicenter, open-label study of CC-98633, BCMA-Targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in subjects with relapsed and/or refractory multiple myeloma.'}",{'NCT04394650'},NCT04394650
1,,,tl-895,FALSE,1,FALSE,FALSE,"This study evaluates TL-895, a tyrosine kinase inhibitor (TKI).","{'This study evaluates TL-895, a tyrosine kinase inhibitor (TKI).', '1 ratio to TL-895 with standard available treatment (SAT), or placebo with SAT.', 'In Part 1, TL-895 open-label will be administered orally at an assigned dose continuously in 7-day cycles for 2 cycles.', 'This is a 2-part study comprising a Phase 1 safety lead-in (Part 1) that will determine the recommended TL-895 dose for Phase 2 (Part 2).', 'A Phase 1/2, Double-Blind, Randomized, Placebo-Controlled Study of TL-895 With Standard Available Treatment Versus Standard Available Treatment for the Treatment of COVID-19 in Patients With Cancer.'}",{'NCT04419623'},NCT04419623
1,,,ker-050,FALSE,1,FALSE,FALSE,"A Phase 2, Open-Label, Ascending Dose Study of KER-050 for the Treatment of Anemia in Patients With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS).","{'A Phase 2, Open-Label, Ascending Dose Study of KER-050 for the Treatment of Anemia in Patients With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS).', 'The purpose of this study is to evaluate the effects of KER-050 on anemia in patients with very low, low or intermediate risk MDS'}",{'NCT04419649'},NCT04419649
1,,,tqb3558,FALSE,1,FALSE,FALSE,"This is a study to evaluate the maximum tolerated dose (MTD) , occurrence of all adverse events (AE) and serious adverse events (SAE) , pharmacokinetic parameters and antitumor effect of TQB3558 tablets in Chinese adult patients with advanced solid tumors .The","{'This is a study to evaluate the maximum tolerated dose (MTD) , occurrence of all adverse events (AE) and serious adverse events (SAE) , pharmacokinetic parameters and antitumor effect of TQB3558 tablets in Chinese adult patients with advanced solid tumors .The', 'A Phase I, Open-label, Dose Escalation and Expansion Study to Evaluate the Tolerance, Efficacy and Pharmacokinetics of TQB3558 Tablets.', 'Phase Ia: dose escalation period, to evaluate the safety and tolerability of TQB3558 tablets, determine MTD; Phase Ib: effectiveness exploration period, to expand the safe and effective dose group, recommend appropriate dosage and method for subsequent clinical research'}",{'NCT04408079'},NCT04408079
1,,,vb-111,FALSE,1,FALSE,FALSE,"A Randomized, Controlled Phase II Surgical Trial to Evaluate Early Immunologic Pharmacodynamic Parameters for the Viral Cancer Therapy Ofranergene Obadenovec (VB-111) in Patients With Surgically Accessible Recurrent/Progressive Glioblastoma.","{'A Randomized, Controlled Phase II Surgical Trial to Evaluate Early Immunologic Pharmacodynamic Parameters for the Viral Cancer Therapy Ofranergene Obadenovec (VB-111) in Patients With Surgically Accessible Recurrent/Progressive Glioblastoma.', 'This research study is studying a new viral cancer therapy, ofranergene obadenovec (VB-111), for recurrent or progressive glioblastoma (GBM), a brain tumor that is growing or progressing despite earlier treatment'}",{'NCT04406272'},NCT04406272
1,,,ofranergene obadenovec,FALSE,1,FALSE,FALSE,"A Randomized, Controlled Phase II Surgical Trial to Evaluate Early Immunologic Pharmacodynamic Parameters for the Viral Cancer Therapy Ofranergene Obadenovec (VB-111) in Patients With Surgically Accessible Recurrent/Progressive Glioblastoma.","{'A Randomized, Controlled Phase II Surgical Trial to Evaluate Early Immunologic Pharmacodynamic Parameters for the Viral Cancer Therapy Ofranergene Obadenovec (VB-111) in Patients With Surgically Accessible Recurrent/Progressive Glioblastoma.', 'This research study is studying a new viral cancer therapy, ofranergene obadenovec (VB-111), for recurrent or progressive glioblastoma (GBM), a brain tumor that is growing or progressing despite earlier treatment'}",{'NCT04406272'},NCT04406272
,1,,ipdr,FALSE,1,FALSE,FALSE,A Phase 1 Study of IPdR in Combination With Capecitabine and Radiotherapy in Rectal Cancer.,{'A Phase 1 Study of IPdR in Combination With Capecitabine and Radiotherapy in Rectal Cancer.'},{'NCT04406857'},NCT04406857
1,,,ropidoxuridine,FALSE,1,FALSE,FALSE,This phase I trial studies the side effects and best dose of ropidoxuridine and how well it works when added to the usual chemotherapy treatment (capecitabine) during radiation therapy for the treatment of patients with stage II-III rectal cancer.,"{'This phase I trial studies the side effects and best dose of ropidoxuridine and how well it works when added to the usual chemotherapy treatment (capecitabine) during radiation therapy for the treatment of patients with stage II-III rectal cancer.', 'Ropidoxuridine may help radiation therapy work better by making cancer cells more sensitive to the radiation therapy.', 'This study is being done to find out whether ropidoxuridine in addition to capecitabine and radiation therapy works better in treating patients with rectal cancer'}",{'NCT04406857'},NCT04406857
1,,,xmt-1592,FALSE,1,FALSE,FALSE,"A Phase 1b, First-in-Human, Dose Escalation and Expansion Study of XMT-1592 In Patients With Solid Tumors Likely to Express NaPi2b.","{'A Phase 1b, First-in-Human, Dose Escalation and Expansion Study of XMT-1592 In Patients With Solid Tumors Likely to Express NaPi2b.', 'Phase 1b, a study in high grade serous ovarian cancer and nonsmall cell lung cancer to evaluate the safety and clinical activity of the antibody-drug conjugate (ADC) XMT-1592'}",{'NCT04396340'},NCT04396340
,,1,ceacam5,FALSE,1,FALSE,FALSE,"Open-label, Single-arm Trial to Evaluate Antitumor Activity, Safety, and Pharmacokinetics of SAR408701 Used in Combination With Ramucirumab in Metastatic, Non-squamous, Non-small-cell Lung Cancer (NSQ NSCLC) Patients With CEACAM5-positive Tumors, Previously Treated With Platinum-based Chemotherapy and an Immune Checkpoint Inhibitor.","{'Open-label, Single-arm Trial to Evaluate Antitumor Activity, Safety, and Pharmacokinetics of SAR408701 Used in Combination With Ramucirumab in Metastatic, Non-squamous, Non-small-cell Lung Cancer (NSQ NSCLC) Patients With CEACAM5-positive Tumors, Previously Treated With Platinum-based Chemotherapy and an Immune Checkpoint Inhibitor.'}",{'NCT04394624'},NCT04394624
1,,,glr2007,FALSE,1,FALSE,FALSE,"An Open-Label, Multicenter, Phase 1b/2 Study to Establish Safety, Tolerability, and Optimal Dosing Strategy of GLR2007 in Subjects With Advanced Solid Tumors.","{'An Open-Label, Multicenter, Phase 1b/2 Study to Establish Safety, Tolerability, and Optimal Dosing Strategy of GLR2007 in Subjects With Advanced Solid Tumors.', 'This study is designed to determine the safety, tolerability, and optimal dosing of GLR2007 in participants with advanced solid tumors that do not respond well to standard clinical therapies'}",{'NCT04444427'},NCT04444427
1,,,cdx-527,FALSE,1,FALSE,FALSE,A Phase 1 Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies.,{'A Phase 1 Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies.'},{'NCT04440943'},NCT04440943
,,1,ozone,FALSE,1,FALSE,FALSE,"d. In our study, we aim to compare the effectiveness of ozone injection in patients diagnosed with trochanteric bursitis and to compare steroid injection with the application of ozone therapy","{'d. In our study, we aim to compare the effectiveness of ozone injection in patients diagnosed with trochanteric bursitis and to compare steroid injection with the application of ozone therapy', 'These treatments include ozone, prolotherapy injection applications, dry needling, acupuncture, hirudotherapy, phytotherapy, mesotherapy, balneotherapy, kinesiobanding, etc.', 'Comparison of Ozone and Steroid Injection in Patients With Trochanteric Bursitis.'}",{'NCT04420572'},NCT04420572
,1,,ono-7913-,FALSE,1,FALSE,FALSE,"An Open-label, Uncontrolled, Dose Escalation Study in Patients With Advanced or Metastatic Solid Cancers (ONO-7913-01).","{'An Open-label, Uncontrolled, Dose Escalation Study in Patients With Advanced or Metastatic Solid Cancers (ONO-7913-01).'}",{'NCT04403308'},NCT04403308
1,,,cartx,FALSE,1,FALSE,FALSE,"CARTx is a new treatment for patients with B-cell malignancies (cancer of the B-cells), and the long-term effects of CARTx on immune function are not yet well understood.","{'CARTx is a new treatment for patients with B-cell malignancies (cancer of the B-cells), and the long-term effects of CARTx on immune function are not yet well understood.'}",{'NCT04410900'},NCT04410900
1,,,sl-172154,FALSE,1,FALSE,FALSE,"This is a Phase 1 first in human, open label, multi-center, dose escalation study to evaluate the safety, tolerability, PK, anti-tumor activity and pharmacodynamic effects of SL-172154 in subjects with ovarian cancer","{'This is a Phase 1 first in human, open label, multi-center, dose escalation study to evaluate the safety, tolerability, PK, anti-tumor activity and pharmacodynamic effects of SL-172154 in subjects with ovarian cancer', 'Phase 1 Dose Escalation Study of the Agonist Redirected Checkpoint, SL-172154 (SIRPα-Fc-CD40L) Administered Intravenously in Subjects With Ovarian Cancer.'}",{'NCT04406623'},NCT04406623
1,,,sar442257,FALSE,1,FALSE,FALSE,"An Open-label, First-in-human, Single Agent, Dose Escalation Study for the Evaluation of Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of SAR442257 in Patients With Relapsed and Refractory Multiple Myeloma and Relapsed and Refractory Non-Hodgkin Lymphoma.","{'An Open-label, First-in-human, Single Agent, Dose Escalation Study for the Evaluation of Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of SAR442257 in Patients With Relapsed and Refractory Multiple Myeloma and Relapsed and Refractory Non-Hodgkin Lymphoma.', 'Primary Objective: To determine the maximum tolerated dose (MTD) of SAR442257 administered as a single agent in patients with relapsed and refractory multiple myeloma (RRMM) and refractory non-Hodgkin lymphoma (RR-NHL), and determine the recommended Phase 2 dose (RP2D) Secondary Objectives: To characterize the safety profile of SAR442257 To characterize the pharmacokinetics (PK) profile of SAR442257 To evaluate the potential immunogenicity of SAR442257 To assess preliminary evidence of antitumor activity'}",{'NCT04401020'},NCT04401020
1,,,dendrobium huoshanense,FALSE,1,FALSE,FALSE,The study evaluates the addition of Chinese Herbal Compound Dendrobium Huoshanense Granules to capecitabine and irinotecan in neoadjuvant chemoradiation(CRT) in locally advanced rectal cancer.,"{'The study evaluates the addition of Chinese Herbal Compound Dendrobium Huoshanense Granules to capecitabine and irinotecan in neoadjuvant chemoradiation(CRT) in locally advanced rectal cancer.', 'A Phase II Randomized Study of the Protection Effect of Chinese Herbal Compound Dendrobium Huoshanense Granules in NCRT for Patients With Locally Advanced Rectal Cancer.'}",{'NCT04394598'},NCT04394598
1,,,azithromycine,FALSE,1,FALSE,FALSE,"Randomised, Double-blind, Placebo-controlled Phase 2 Study Evaluating the Efficacy of Hydroxychloroquine and Azithromycine in Patients With COVID-19 and Hematological Malignancies.","{'Randomised, Double-blind, Placebo-controlled Phase 2 Study Evaluating the Efficacy of Hydroxychloroquine and Azithromycine in Patients With COVID-19 and Hematological Malignancies.', 'The primary objective of this phase 2, multicentric, placebo-controlled double-blind, randomized study is to evaluate the efficacy of the combination of hydroxychloroquine and azithromycine on the viral load drop at day 5 among patients with COVID-19 and hematological malignancies'}",{'NCT04392128'},NCT04392128
,1,,ppix,FALSE,1,FALSE,FALSE,"The phase II study evaluate a light dose escalation in a classical intraoperative PDT regimen mediated by 5-ALA-PpIX, in glioblastoma patients with access to full surgical removal of the contrast enhancement.","{'The phase II study evaluate a light dose escalation in a classical intraoperative PDT regimen mediated by 5-ALA-PpIX, in glioblastoma patients with access to full surgical removal of the contrast enhancement.'}",{'NCT04391062'},NCT04391062
,1,,5-ala,FALSE,1,FALSE,FALSE,"The phase II study evaluate a light dose escalation in a classical intraoperative PDT regimen mediated by 5-ALA-PpIX, in glioblastoma patients with access to full surgical removal of the contrast enhancement.","{'The phase II study evaluate a light dose escalation in a classical intraoperative PDT regimen mediated by 5-ALA-PpIX, in glioblastoma patients with access to full surgical removal of the contrast enhancement.'}",{'NCT04391062'},NCT04391062
1,,,sgn-b6a,FALSE,1,FALSE,FALSE,Part A of the study will find out how much SGN-B6A should be given to participants.,"{'Part A of the study will find out how much SGN-B6A should be given to participants.', 'It will study SGN-B6A to find out what its side effects are.', 'A Phase 1 Study of SGN-B6A in Advanced Solid Tumors.', 'This trial will look at a drug called SGN-B6A to find out whether it is safe for people who have solid tumors.', 'Part B will use the dose found in Part A to find out how safe SGN-B6A is and if it works to treat solid tumors', 'It will also study whether SGN-B6A works to treat solid tumors.'}",{'NCT04389632'},NCT04389632
1,,,almonertinib,FALSE,1,FALSE,FALSE,"This is a multicenter, randomized, controlled, phase II study assessing the efficacy and safety of Almonertinib compared Erlotinib or platinum doublet chemotherapy (carboplatin or cisplatin + pemetrexed) as neoadjuvant therapy to EGFRm+ IIIA-N2 NSCLC patients","{'This is a multicenter, randomized, controlled, phase II study assessing the efficacy and safety of Almonertinib compared Erlotinib or platinum doublet chemotherapy (carboplatin or cisplatin + pemetrexed) as neoadjuvant therapy to EGFRm+ IIIA-N2 NSCLC patients'}",{'NCT04455594'},NCT04455594
1,,,evx-02,FALSE,1,FALSE,FALSE,"A Phase 1/2, Study of Adjuvant Immunotherapy With EVX-02 and Anti-PD-1 After Complete Resection of Stage IIIB/IIIC/IIID or Stage IV Melanoma in Patients at High Risk for Recurrence.","{'A Phase 1/2, Study of Adjuvant Immunotherapy With EVX-02 and Anti-PD-1 After Complete Resection of Stage IIIB/IIIC/IIID or Stage IV Melanoma in Patients at High Risk for Recurrence.'}",{'NCT04455503'},NCT04455503
,1,,radr,FALSE,1,FALSE,FALSE,"A Phase 1 Study of Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies.","{'A Phase 1 Study of Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies.'}",{'NCT04447027'},NCT04447027
,1,,tme,FALSE,1,FALSE,FALSE,"TASOX can be safely and efficaciously delivered after short course radiation, resulting in significant pathologic downstaging, allowing for an R0 pelvic resection, and providing local control in appropriately selected stage II/III rectal cancer patients treated with contemporary TME-based surgery","{'TASOX can be safely and efficaciously delivered after short course radiation, resulting in significant pathologic downstaging, allowing for an R0 pelvic resection, and providing local control in appropriately selected stage II/III rectal cancer patients treated with contemporary TME-based surgery'}",{'NCT04417699'},NCT04417699
,1,,tasox,FALSE,1,FALSE,FALSE,"SHORT: SHOrt Course Radiation and TASOX (TAS102 Plus Oxaliplatin) Chemotherapy in Operable Rectal Cancer, a Phase II Trial.","{'SHORT: SHOrt Course Radiation and TASOX (TAS102 Plus Oxaliplatin) Chemotherapy in Operable Rectal Cancer, a Phase II Trial.', 'TASOX can be safely and efficaciously delivered after short course radiation, resulting in significant pathologic downstaging, allowing for an R0 pelvic resection, and providing local control in appropriately selected stage II/III rectal cancer patients treated with contemporary TME-based surgery'}",{'NCT04417699'},NCT04417699
1,,,asn004,FALSE,1,FALSE,FALSE,The study will test various doses of ASN004 to find out the highest safe dose to test in future trials.,"{'The study will test various doses of ASN004 to find out the highest safe dose to test in future trials.', 'An Open Label, Multicenter, Dose-Finding Clinical Phase 1 Study of ASN004 to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy in Patients With Advanced Malignant Solid Tumors.', 'Participants in this study will receive ASN004 once every 3 weeks by intravenous infusion.'}",{'NCT04410224'},NCT04410224
1,,,qbs10072s,FALSE,1,FALSE,FALSE,The MTD of QBS10072S will be confirmed in patients with relapsed or refractory grade 4 astrocytoma,"{'The MTD of QBS10072S will be confirmed in patients with relapsed or refractory grade 4 astrocytoma', 'A Phase 1, Open Label, Multi-Center, Single and Multiple Dose, Dose Escalation and Expansion Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S in Previously Treated Patients With Advanced or Metastatic Cancers With High LAT1 Signatures, and in Patients With Relapsed or Refractory Grade 4 Astrocytoma.', 'This is a multi-center, open-label, dose escalation study to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and maximum tolerated dose (MTD) of QBS10072S in patients with advanced or metastatic cancers with high LAT1 expression.'}",{'NCT04430842'},NCT04430842
,,1,chemoplaque,FALSE,1,FALSE,FALSE,Phase I Sustained-Release Topotecan Episcleral Plaque (Chemoplaque) for Retinoblastoma.,{'Phase I Sustained-Release Topotecan Episcleral Plaque (Chemoplaque) for Retinoblastoma.'},{'NCT04428879'},NCT04428879
1,,,cc-94676,FALSE,1,FALSE,FALSE,"A Phase 1, Multi-center, Open-label, Dose Finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CC-94676 in Subjects With Metastatic Castration-Resistant Prostate Cancer.","{'A Phase 1, Multi-center, Open-label, Dose Finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CC-94676 in Subjects With Metastatic Castration-Resistant Prostate Cancer.', 'This is a first in human study to assess the safety, tolerability, PK, PD and preliminary efficacy of CC-94676 in men with progressive metastatic castration-resistant prostate cancer'}",{'NCT04428788'},NCT04428788
1,,,ta1,FALSE,1,FALSE,FALSE,It is our hypothesis that a course of Ta1 administered to individuals with ESRD will reduce the rate and severity of infection with COVID-19,"{'It is our hypothesis that a course of Ta1 administered to individuals with ESRD will reduce the rate and severity of infection with COVID-19', 'Ta1 has been shown to be safely administered to hemodialysis patients.'}",{'NCT04428008'},NCT04428008
1,,,allo-501a,FALSE,1,FALSE,FALSE,"A Single-Arm, Open-Label, Phase 1/2 Study Evaluating the Safety, Efficacy, and Cellular Kinetics/Pharmacodynamics of ALLO-501A, an Anti-CD19 Allogeneic CAR T Cell Therapy in Subjects With Relapsed/Refractory Large B-Cell Lymphoma (LBCL).","{'A Single-Arm, Open-Label, Phase 1/2 Study Evaluating the Safety, Efficacy, and Cellular Kinetics/Pharmacodynamics of ALLO-501A, an Anti-CD19 Allogeneic CAR T Cell Therapy in Subjects With Relapsed/Refractory Large B-Cell Lymphoma (LBCL).', 'The purpose of the ALPHA-2 study is to assess the safety, efficacy, and cell kinetics of ALLO-501A in adults with relapsed or refractory large B-cell lymphoma after a lymphodepletion regimen comprising fludarabine, cyclophosphamide, and ALLO-647'}",{'NCT04416984'},NCT04416984
1,,,allo-647,FALSE,1,FALSE,FALSE,"The purpose of the ALPHA-2 study is to assess the safety, efficacy, and cell kinetics of ALLO-501A in adults with relapsed or refractory large B-cell lymphoma after a lymphodepletion regimen comprising fludarabine, cyclophosphamide, and ALLO-647","{'The purpose of the ALPHA-2 study is to assess the safety, efficacy, and cell kinetics of ALLO-501A in adults with relapsed or refractory large B-cell lymphoma after a lymphodepletion regimen comprising fludarabine, cyclophosphamide, and ALLO-647'}",{'NCT04416984'},NCT04416984
1,,,carrimycin,FALSE,1,FALSE,FALSE,"Safety and Efficacy Evaluation of Carrimycin in Patients With Locally Advanced, Recurrent, or Metastatic Head and Neck Squamous Cell Carcinoma (Non NPC):","{'Safety and Efficacy Evaluation of Carrimycin in Patients With Locally Advanced, Recurrent, or Metastatic Head and Neck Squamous Cell Carcinoma (Non NPC):', 'The trial is a study conducted to evaluate the safety, tolerability and PK characteristics of Carrimycin tablet and measure its anti-tumor efficacy initially in the treatment of patients with locally advanced, recurrent, or metastatic head and neck squamous cell carcinoma (non NPC)'}",{'NCT04413214'},NCT04413214
,1,,fdg,FALSE,1,FALSE,FALSE,"Although some studies reported a relatively high sensitivity of FDG-PET/CT for pancreatic cancer, FDG uptake in these tumors is usually only slightly higher than the mean SUV of the pancreas itself [10].","{'Although some studies reported a relatively high sensitivity of FDG-PET/CT for pancreatic cancer, FDG uptake in these tumors is usually only slightly higher than the mean SUV of the pancreas itself [10].', 'The aim of the suggested study is to assess the added value of 68Ga-FAPI-04 PET/CT over 18F-FDG PET/CT in evaluating the extent of disease in pancreatic and gastric cancer, malignancies that are known to show variable FDG-avidity, at times, no uptake at all.'}",{'NCT04441606'},NCT04441606
1,,,68ga-fapi-04,FALSE,1,FALSE,FALSE,The Role of 68Ga-FAPI-04 PET/CT in Gastric and Pancreatic Cancers.,{'The Role of 68Ga-FAPI-04 PET/CT in Gastric and Pancreatic Cancers.'},{'NCT04441606'},NCT04441606
1,,,68ga-,FALSE,1,FALSE,FALSE,"The aim of the suggested study is to assess the added value of 68Ga-FAPI-04 PET/CT over 18F-FDG PET/CT in evaluating the extent of disease in pancreatic and gastric cancer, malignancies that are known to show variable FDG-avidity, at times, no uptake at all.","{'The aim of the suggested study is to assess the added value of 68Ga-FAPI-04 PET/CT over 18F-FDG PET/CT in evaluating the extent of disease in pancreatic and gastric cancer, malignancies that are known to show variable FDG-avidity, at times, no uptake at all.'}",{'NCT04441606'},NCT04441606
1,,,18f-fdg,FALSE,1,FALSE,FALSE,"The aim of the suggested study is to assess the added value of 68Ga-FAPI-04 PET/CT over 18F-FDG PET/CT in evaluating the extent of disease in pancreatic and gastric cancer, malignancies that are known to show variable FDG-avidity, at times, no uptake at all.","{'The aim of the suggested study is to assess the added value of 68Ga-FAPI-04 PET/CT over 18F-FDG PET/CT in evaluating the extent of disease in pancreatic and gastric cancer, malignancies that are known to show variable FDG-avidity, at times, no uptake at all.'}",{'NCT04441606'},NCT04441606
,1,,mxeloxiri,FALSE,1,FALSE,FALSE,A Multicenter Randomized Controlled Phase II Trial of Neoadjuvant mXELOXIRI Versus Routine Chemoradiotherapy in the EMVI Positive Locally Advanced Rectal Cancer (TRICHEMO).,{'A Multicenter Randomized Controlled Phase II Trial of Neoadjuvant mXELOXIRI Versus Routine Chemoradiotherapy in the EMVI Positive Locally Advanced Rectal Cancer (TRICHEMO).'},{'NCT04423965'},NCT04423965
,1,,xeloxiri,FALSE,1,FALSE,FALSE,The study is to evaluate the efficacy and safety of XELOXIRI as neoadjuvant chemotherapy alone for EMVI+ LARC in contrast to the efficacy of standard Chemoradiotherapy (CRT),{'The study is to evaluate the efficacy and safety of XELOXIRI as neoadjuvant chemotherapy alone for EMVI+ LARC in contrast to the efficacy of standard Chemoradiotherapy (CRT)'},{'NCT04423965'},NCT04423965
1,,,bo-112,FALSE,1,FALSE,FALSE,This phase I trial studies the side effects of BO-112 when given together with nivolumab before surgery in treating patients with soft tissue sarcoma that can be removed by surgery (resectable).,"{'This phase I trial studies the side effects of BO-112 when given together with nivolumab before surgery in treating patients with soft tissue sarcoma that can be removed by surgery (resectable).', 'Giving nivolumab and BO-112 before surgery may work better in treating patients with soft tissue sarcoma compared to nivolumab alone', ""Immunotherapy with BO-112, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread.""}",{'NCT04420975'},NCT04420975
1,,,bo 112,FALSE,1,FALSE,FALSE,A Phase I Study of Nivolumab and Intratumoral BO 112 for Resectable Soft Tissue Sarcoma.,{'A Phase I Study of Nivolumab and Intratumoral BO 112 for Resectable Soft Tissue Sarcoma.'},{'NCT04420975'},NCT04420975
1,,,nm21-1480,FALSE,1,FALSE,FALSE,A Phase 1/2 Study of NM21-1480 (Anti-PDL-1/Anti-4-1BB/Anti-HSA Tri-Specific Antibody) in Adult Patients With Advanced Solid Tumors.,"{'A Phase 1/2 Study of NM21-1480 (Anti-PDL-1/Anti-4-1BB/Anti-HSA Tri-Specific Antibody) in Adult Patients With Advanced Solid Tumors.', 'This is a first-in-human, open-label, multi-center, Phase 1/2, dose-escalation study with expansion cohorts to evaluate NM21-1480 for safety and immunogenicity, to determine the maximal tolerated dose and recommended Phase 2 dose, define the pharmacokinetics, to explore the pharmacodynamics, and to obtain preliminary evidence of the clinical activity in adult patients with selected advanced solid tumors'}",{'NCT04442126'},NCT04442126
,1,,leap-009,FALSE,1,FALSE,FALSE,"A Phase 2, Randomized, Open-label Three-arm Clinical Study to Evaluate the Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) That Have Progressed After Platinum Therapy and Immunotherapy (PD-1/PD-L1 Inhibitors) (LEAP-009).","{'A Phase 2, Randomized, Open-label Three-arm Clinical Study to Evaluate the Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) That Have Progressed After Platinum Therapy and Immunotherapy (PD-1/PD-L1 Inhibitors) (LEAP-009).'}",{'NCT04428151'},NCT04428151
,1,,castration,FALSE,1,FALSE,FALSE,Prospective Biomarker Analysis of Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Undergoing Bipolar Androgen Therapy (BAT).,{'Prospective Biomarker Analysis of Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Undergoing Bipolar Androgen Therapy (BAT).'},{'NCT04424654'},NCT04424654
1,,,68gallium-psma,FALSE,1,FALSE,FALSE,"During the study period, patients will have plasma collected for cell-free tumor DNA analysis and CTC ARV7 status and also will perform 68Gallium-PSMA PET at baseline and then every 6 weeks","{'During the study period, patients will have plasma collected for cell-free tumor DNA analysis and CTC ARV7 status and also will perform 68Gallium-PSMA PET at baseline and then every 6 weeks'}",{'NCT04424654'},NCT04424654
,1,,-cls-579,FALSE,1,FALSE,FALSE,Participants will receive oral ABBV-CLS-579 capsule alone or in combination with intravenous (IV) PD-1 inhibitor.,{'Participants will receive oral ABBV-CLS-579 capsule alone or in combination with intravenous (IV) PD-1 inhibitor.'},{'NCT04417465'},NCT04417465
,1,,cls-579,FALSE,1,FALSE,FALSE,The purpose of this study is to see how safe and effective ABBV-CLS-579 is when used alone or in combination with programmed cell death protein-1 (PD-1) inhibitors in treating solid cancers.,"{'The purpose of this study is to see how safe and effective ABBV-CLS-579 is when used alone or in combination with programmed cell death protein-1 (PD-1) inhibitors in treating solid cancers.', 'In the monotherapy arm, participants will receive ABBV-CLS-579 alone, in increasing doses.', 'In the combination therapy arm, escalating doses of ABBV-CLS-579 will be given in combination with a PD-1 inhibitor.'}",{'NCT04417465'},NCT04417465
1,,,abbv-cls-579,FALSE,1,FALSE,FALSE,"A Phase 1, Multi-center, Open Label First-in-Human Study With ABBV-CLS-579 Alone and in Combination With Anti-PD-1 in Subjects With Locally Advanced or Metastatic Tumors.","{'A Phase 1, Multi-center, Open Label First-in-Human Study With ABBV-CLS-579 Alone and in Combination With Anti-PD-1 in Subjects With Locally Advanced or Metastatic Tumors.', 'ABBV-CLS-579 is an investigational drug being developed for the treatment of solid tumors.'}",{'NCT04417465'},NCT04417465
,1,,gped,FALSE,1,FALSE,FALSE,"The purpose of this study is to evaluate the efficacy and safety of gemcitabine, pegaspargase, etoposide, and dexamethasone (GPED) in the treatment of Relapsed/Refractory or advanced NK/T-cell lymphoma patients (ENKTCL)","{'The purpose of this study is to evaluate the efficacy and safety of gemcitabine, pegaspargase, etoposide, and dexamethasone (GPED) in the treatment of Relapsed/Refractory or advanced NK/T-cell lymphoma patients (ENKTCL)', 'Gemcitabine, Pegaspargase, Etoposide, and Dexamethasone (GPED) for Patients With Relapsed/Refractory or Advanced NK/T-cell Lymphoma : a Single Arm,Open-lable,Phase II Study.'}",{'NCT04405375'},NCT04405375
1,,,ono-7913,FALSE,1,FALSE,FALSE,"To assess the tolerability, safety, and pharmacokinetics (PK) of ONO-7913 in patients with advanced or metastatic solid cancers and explore its efficacy and biomarkers","{'To assess the tolerability, safety, and pharmacokinetics (PK) of ONO-7913 in patients with advanced or metastatic solid cancers and explore its efficacy and biomarkers'}",{'NCT04403308'},NCT04403308
,1,,fus,FALSE,1,FALSE,FALSE,"This is a prospective, single-arm, two stages, open-label, pilot study to investigate the efficacy and safety of FUS add-on bevacizumab (BEV) in rGBM patients.","{'This is a prospective, single-arm, two stages, open-label, pilot study to investigate the efficacy and safety of FUS add-on bevacizumab (BEV) in rGBM patients.'}",{'NCT04446416'},NCT04446416
,1,,sodium,FALSE,1,FALSE,FALSE,"Initial therapy should be supportive and involves restricting dietary protein and sodium intake, controlling blood pressure, hyperlipidemia, and edema.","{'Initial therapy should be supportive and involves restricting dietary protein and sodium intake, controlling blood pressure, hyperlipidemia, and edema.'}",{'NCT04424862'},NCT04424862
,1,,vitd,FALSE,1,FALSE,FALSE,All patients of both arms will receive a prephase with oral prednisone before 6 cycles Q21 of immunochemotherapy with R-CHOP or R-miniCHOP at standard doses; patients in the Experimental arm (Arm B) will receive also a prephase therapy with VitD and a supplementation of VitD during the intere period of immunochemotherapy according to a prefixed schedule.,{'All patients of both arms will receive a prephase with oral prednisone before 6 cycles Q21 of immunochemotherapy with R-CHOP or R-miniCHOP at standard doses; patients in the Experimental arm (Arm B) will receive also a prephase therapy with VitD and a supplementation of VitD during the intere period of immunochemotherapy according to a prefixed schedule.'},{'NCT04442412'},NCT04442412
1,,,avatrombopag,FALSE,1,FALSE,FALSE,The study will also test whether avatrombopag can continue to be effective against thrombocytopenia while participants are on chemotherapy for 12 weeks or longer.,"{'The study will also test whether avatrombopag can continue to be effective against thrombocytopenia while participants are on chemotherapy for 12 weeks or longer.', 'Researchers will look at whether giving participants avatrombopag for 3 weeks can raise their platelet levels enough for them to begin chemotherapy.', 'Clinical Trial of Avatrombopag for Thrombocytopenia in Cancer, A Phase II Single Arm Study.', 'This study will test whether avatrombopag is an effective treatment for thrombocytopenia in people who have both cancer and a liver disease (such as cirrhosis, cholangitis, or hepatitis).'}",{'NCT04437953'},NCT04437953
1,,,tipiracil,FALSE,1,FALSE,FALSE,"A Randomized, Phase II Study Comparing the Sequences of Regorafenib and Trifluridine/Tipiracil, After Failure of Standard Therapies in Patients With Metastatic Colorectal Cancer.","{'A Randomized, Phase II Study Comparing the Sequences of Regorafenib and Trifluridine/Tipiracil, After Failure of Standard Therapies in Patients With Metastatic Colorectal Cancer.', 'A randomized, phase II study comparing the sequences of regorafenib and trifluridine/tipiracil, after failure of standard therapies in patients with metastatic colorectal cancer'}",{'NCT04450836'},NCT04450836
,,1,amyloid,FALSE,1,FALSE,FALSE,"The study will see if BCG vaccination will alter a plasma test for amyloid, a biomarker for cerebral amyloid","{'The study will see if BCG vaccination will alter a plasma test for amyloid, a biomarker for cerebral amyloid'}",{'NCT04449926'},NCT04449926
1,,,lasofoxifene,FALSE,1,FALSE,FALSE,"An Open-label, Multicenter Study Evaluating the Safety of Lasofoxifene in Combination With Abemaciclib for the Treatment of Pre- and Postmenopausal Women With Locally Advanced or Metastatic ER+/HER2− Breast Cancer and Have an ESR1 Mutation ( ELAINEII ).","{'An Open-label, Multicenter Study Evaluating the Safety of Lasofoxifene in Combination With Abemaciclib for the Treatment of Pre- and Postmenopausal Women With Locally Advanced or Metastatic ER+/HER2− Breast Cancer and Have an ESR1 Mutation ( ELAINEII ).', 'This is an open-label, multicenter, single-arm safety study evaluating the safety and tolerability of the lasofoxifene and abemaciclib combination for the treatment of pre- and postmenopausal women with locally advanced or metastatic ER+/HER2− breast cancer who have disease progression on first and/or 2nd lines of hormonal treatment for metastatic disease and have an ESR1 mutation'}",{'NCT04432454'},NCT04432454
,1,,ponticelli regimen,FALSE,1,FALSE,FALSE,Ponticelli regimen: Cyclical corticosteroid/alkylating-agent therapy for IMN.,"{'Ponticelli regimen: Cyclical corticosteroid/alkylating-agent therapy for IMN.', 'In this prospective multicenter randomized trial, we compared the efficacy between multitarget therapy and Ponticelli regimen.', '2. that multitarget therapy reduces the number of relapses (efficacy in sustaining remission) and increases the time to relapse when compared with treatment with Ponticelli regimen.', 'Trial Aims and Hypothesis The specific aims of this trial are to test the hypothesis 1. that multitarget therapy is non-inferior to Ponticelli regimen in inducing long-term remission (CR or PR) of proteinuria in patients with IMN.', '3. that multitarget therapy has a better side-effect profile when compared with treatment with Ponticelli regimen in patients with IMN.', 'Randomization and Treatment Groups Once all entry criteria have been satisfied and confirmed, patients will be randomized to treatment with multitarget therapy or Ponticelli regimen.'}",{'NCT04424862'},NCT04424862
1,,,ciclosporin,FALSE,1,FALSE,FALSE,"Multitarget therapy: Combination with prednisone, ciclosporin and mycophenolate mofetil.","{'Multitarget therapy: Combination with prednisone, ciclosporin and mycophenolate mofetil.'}",{'NCT04424862'},NCT04424862
1,,,zumab,FALSE,1,TRUE,FALSE,"This is a multi-center, Phase 2, open-label, single dose level study of PRL3-zumab monotherapy in patients with unresectable or metastatic solid tumor","{'This is a multi-center, Phase 2, open-label, single dose level study of PRL3-zumab monotherapy in patients with unresectable or metastatic solid tumor', 'An Open Label, Multicenter, Safety and Efficacy Phase 2 Study of PRL3-Zumab in Solid Tumors.'}",{'NCT04452955'},NCT04452955
,1,,svd,FALSE,1,FALSE,FALSE,"A Phase 2b, Open-label, Multi-arm Clinical Trial of Selinexor Plus Low-dose Dexamethasone (Sd) in Patients With Penta-refractory Multiple Myeloma or Selinexor and Bortezomib Plus Low-dose Dexamethasone (SVd) in Patients With Triple-class Refractory Multiple Myeloma.","{'A Phase 2b, Open-label, Multi-arm Clinical Trial of Selinexor Plus Low-dose Dexamethasone (Sd) in Patients With Penta-refractory Multiple Myeloma or Selinexor and Bortezomib Plus Low-dose Dexamethasone (SVd) in Patients With Triple-class Refractory Multiple Myeloma.'}",{'NCT04414475'},NCT04414475
1,,,sh3051,FALSE,1,FALSE,FALSE,The second objective is to evaluate the PK profile and preliminary efficacy of SH3051 solid tumors,"{'The second objective is to evaluate the PK profile and preliminary efficacy of SH3051 solid tumors', 'A Phase I, Open-Label Study to Determine Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Efficacy of SH3051 Capsule in Patients With Advanced Solid Tumors.', 'The primary objective is to determine the safety profile of SH3051 in subjects with advanced solid tumors.'}",{'NCT04423380'},NCT04423380
1,,,ds-1055a,FALSE,1,FALSE,FALSE,"A Phase 1, First In Human Study of DS-1055a in Subjects With Relapsed or Refractory Locally Advanced or Metastatic Solid Tumors.","{'A Phase 1, First In Human Study of DS-1055a in Subjects With Relapsed or Refractory Locally Advanced or Metastatic Solid Tumors.', 'The purpose of this study is to assess the safety and tolerability of DS-1055a in participants with relapsed or refractory locally advanced or metastatic solid tumors for which no standard treatment is available'}",{'NCT04419532'},NCT04419532
1,,,bnt151,FALSE,1,FALSE,FALSE,Part 2B is the expansion phase where a predefined number of patients in each indication cohort will be treated with the confirmed recommended phase II dose (RP2D) of BNT151 in combination with respective SoC,"{'Part 2B is the expansion phase where a predefined number of patients in each indication cohort will be treated with the confirmed recommended phase II dose (RP2D) of BNT151 in combination with respective SoC', 'Phase I/IIa, First-in-human, Open-label, Dose Escalation Trial With Expansion Cohorts to Evaluate Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of BNT151 as a Monotherapy and in Combination With Other Anti-cancer Agents in Patients With Solid Tumors.', 'During combination dose escalation (Part 2A), patients of different specific solid tumors (one cohort per indication) will be enrolled and treated with a combination of BNT151 and the respective standard of care (SoC) treatment.', 'This is an open-label, multicenter Phase I/IIa dose escalation, safety, pharmacokinetic (PK) and pharmacodynamic (PD) trial of BNT151 with expansion cohorts in various solid tumor indications.'}",{'NCT04455620'},NCT04455620
1,,,gdc-6036,FALSE,1,FALSE,FALSE,"A Phase I Dose-Escalation and Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-6036 in Patients With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation.","{'A Phase I Dose-Escalation and Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-6036 in Patients With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation.', 'This is a Phase I dose-escalation and dose-expansion study that will evaluate the safety, pharmacokinetics (PK), and preliminary activity of GDC-6036 in patients with advanced or metastatic solid tumors with a KRAS G12C mutation'}",{'NCT04449874'},NCT04449874
1,,,elemene,FALSE,1,FALSE,FALSE,The purpose of this study is to evaluate the synergistic effect and safety of Elemene plus TKIs in EGFR-mutated advanced non-small cell lung cancer,"{'The purpose of this study is to evaluate the synergistic effect and safety of Elemene plus TKIs in EGFR-mutated advanced non-small cell lung cancer', 'Synergistic Real-World Study and Evidence-based Medicine Evaluation of Elemene Combined With Tyrosine Kinase Inhibitors（TKIs）in the Treatment of Advanced Non-small Cell Lung Cancer (NSCLC): Prospective Study.'}",{'NCT04401059'},NCT04401059
1,,,stimvax,FALSE,1,FALSE,FALSE,Phase IIB Open-Label Study to Assess the Safety and Efficacy of STIMVAX® as Third-line Therapy for Metastatic Colorectal Cancer.,{'Phase IIB Open-Label Study to Assess the Safety and Efficacy of STIMVAX® as Third-line Therapy for Metastatic Colorectal Cancer.'},{'NCT04444622'},NCT04444622
1,,,gen1044,FALSE,1,FALSE,FALSE,"First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1044 in Subjects With Malignant Solid Tumors.","{'First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1044 in Subjects With Malignant Solid Tumors.', 'The purpose of the trial is to evaluate the safety, determine the recommended phase 2 dose, and assess preliminary clinical activity of GEN1044 in subjects with solid tumors'}",{'NCT04424641'},NCT04424641
1,,,ropivacaine,FALSE,1,FALSE,FALSE,Study aims to compare the influence of intravenous lidocaine and peridural ropivacaine on postoperative long and short term outcome in patients with pancreatic cancer undergoing surgery.,{'Study aims to compare the influence of intravenous lidocaine and peridural ropivacaine on postoperative long and short term outcome in patients with pancreatic cancer undergoing surgery.'},{'NCT04449289'},NCT04449289
1,,,nfx-179,FALSE,1,FALSE,FALSE,"This study will enroll and treat subjects with cutaneous neurofibromas with NFX-179, a topical study drug.","{'This study will enroll and treat subjects with cutaneous neurofibromas with NFX-179, a topical study drug.', '3 of the treatment groups will receive a specific dose NFX-179, and 1 group will receive placebo.'}",{'NCT04435665'},NCT04435665
,1,,nfx-179 gel,FALSE,1,FALSE,FALSE,"A Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Phase 2a Study to Determine Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Activity of NFX-179 Gel in Subjects With Cutaneous Neurofibromas.","{'A Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Phase 2a Study to Determine Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Activity of NFX-179 Gel in Subjects With Cutaneous Neurofibromas.'}",{'NCT04435665'},NCT04435665
,,,nitrosoureas,FALSE,1,FALSE,FALSE,"- To evaluate the proportion of patients with advanced rare cancers who have objective responses (OR) to treatment with nilotinib and paclitaxel Exploratory Objectives: - To evaluate the proportion of patients alive and progression free at 6 months on study agents - To identify genomic and transcriptomic determinants of response and resistance in tumor biopsy specimens - To examine genomic alterations in circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs) that may be associated with response or resistance - To evaluate the pharmacodynamic effects of the combination on biomarkers of cell death and epithelial-to-mesenchymal transition in tumor tissue and CTCs Eligibility: - Study participants must have a histologically confirmed solid tumor meeting the RARECARE definition of rare tumor that has progressed on standard therapy known to prolong survival or for which no standard treatment options exist - Age >= 18 - No major surgery, radiation, or chemotherapy within 3 weeks prior to entering the study (6 weeks for nitrosoureas and mitomycin C) or 5 half-lives of the agent, whichever is shorter;","{'- To evaluate the proportion of patients with advanced rare cancers who have objective responses (OR) to treatment with nilotinib and paclitaxel Exploratory Objectives: - To evaluate the proportion of patients alive and progression free at 6 months on study agents - To identify genomic and transcriptomic determinants of response and resistance in tumor biopsy specimens - To examine genomic alterations in circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs) that may be associated with response or resistance - To evaluate the pharmacodynamic effects of the combination on biomarkers of cell death and epithelial-to-mesenchymal transition in tumor tissue and CTCs Eligibility: - Study participants must have a histologically confirmed solid tumor meeting the RARECARE definition of rare tumor that has progressed on standard therapy known to prolong survival or for which no standard treatment options exist - Age >= 18 - No major surgery, radiation, or chemotherapy within 3 weeks prior to entering the study (6 weeks for nitrosoureas and mitomycin C) or 5 half-lives of the agent, whichever is shorter;'}",{'NCT04449549'},NCT04449549
,1,,poly adenosine diphosphate (adp)-ribose,FALSE,1,FALSE,FALSE,"Poly adenosine diphosphate (ADP)-ribose polymerase (PARP) inhibitors, such as rucaparib, fight prostate cancer by prevent tumor cells from repairing their DNA.","{'Poly adenosine diphosphate (ADP)-ribose polymerase (PARP) inhibitors, such as rucaparib, fight prostate cancer by prevent tumor cells from repairing their DNA.'}",{'NCT04455750'},NCT04455750
1,,,an0025,FALSE,1,FALSE,FALSE,"All enrolled patients will be treated with AN0025 and Pembrolizumab until the patient experiences disease progression, unacceptable toxicity or withdraws consent, or for a maximum of 35 cycles (approximately 2 years).","{'All enrolled patients will be treated with AN0025 and Pembrolizumab until the patient experiences disease progression, unacceptable toxicity or withdraws consent, or for a maximum of 35 cycles (approximately 2 years).', 'This is an open-label, multicenter, phase Ib study to evaluate the safety and preliminary efficacy of AN0025 in combination with pembrolizumab in patients with locally advanced/metastatic tumors.', 'An Open-Label Multicenter Phase Ib Study of AN0025 in Combination With Pembrolizumab in Patients With Advanced Solid Tumors.', 'The dose of pembrolizumab will remain constant at 200 mg every 3 weeks (Q3W) for each dose level of AN0025 and in each cohort'}",{'NCT04432857'},NCT04432857
1,,,ranitidine,FALSE,1,FALSE,FALSE,Some ranitidine medicines contain an impurity called N-nitrosodimethylamine (NDMA) at low levels.,"{'Some ranitidine medicines contain an impurity called N-nitrosodimethylamine (NDMA) at low levels.', 'Similarly, if ranitidine is exposed to a simulated small intestinal fluid, NDMA is not formed.', 'Ranitidine is an over-the-counter and prescription drug, which decreases the amount of acid secreted by the stomach.', 'FDA has also conducted tests that simulate the potential formation of NDMA from ranitidine after it has been exposed to acid in the stomach with a normal diet.', 'Of note, the risk of NDMA with ranitidine is only relevant with prolonged chronic administration as at the acceptable limit, there is approximately a 1 in 100,000 chance of cancer after 70 years of exposure to that level.', 'On 4 different days, each participant will receive ranitidine or placebo with high nitrite/NDMA meals and ranitidine or placebo with low nitrite/NDMA meals', 'Separately, a previous study in 10 healthy volunteers showed that volunteers who received ranitidine had an increase in urinary NDMA excreted over 24 h. The level of increase was greater than would be expected from laboratory testing.', 'The study will use a prescription dose of ranitidine (300 mg) to test whether there is increased urinary NDMA excretion levels over 24-hours after ranitidine administration in comparison to placebo when participants are administered low nitrite/NDMA meals and when subjects are administered high nitrite/NDMA meals.', 'The ranitidine that will be used in this study has been tested twice (months apart) and shown to have stable NDMA levels well below the acceptable daily limit.', 'The US Food and Drug Administration (FDA) has found levels of NDMA in some ranitidine products similar to the levels you would expect to be exposed to if you ate common foods like grilled or smoked meats.', 'Clinical Study to Investigate the Urinary Excretion of N-nitrosodimethylamine (NDMA) After Ranitidine Administration.', 'This clinical study is being performed to determine if and how much NDMA is produced from ranitidine in the human body and whether nitrite-containing foods may increase formation of NDMA.'}",{'NCT04397445'},NCT04397445
,1,,n-nitrosodimethylamine,FALSE,1,FALSE,FALSE,Some ranitidine medicines contain an impurity called N-nitrosodimethylamine (NDMA) at low levels.,"{'Some ranitidine medicines contain an impurity called N-nitrosodimethylamine (NDMA) at low levels.', 'Clinical Study to Investigate the Urinary Excretion of N-nitrosodimethylamine (NDMA) After Ranitidine Administration.'}",{'NCT04397445'},NCT04397445
,,1,ndma,FALSE,1,FALSE,FALSE,Some ranitidine medicines contain an impurity called N-nitrosodimethylamine (NDMA) at low levels.,"{'Some ranitidine medicines contain an impurity called N-nitrosodimethylamine (NDMA) at low levels.', 'Similarly, if ranitidine is exposed to a simulated small intestinal fluid, NDMA is not formed.', 'FDA has also conducted tests that simulate the potential formation of NDMA from ranitidine after it has been exposed to acid in the stomach with a normal diet.', 'Other laboratory experiments suggest a combination of nitrites, such as found in processed meats, and an acidic environment may increase NDMA formation, however the levels of nitrites tested were very high.', 'Results of these tests indicate that NDMA is not formed in typical stomach conditions.', 'On 4 different days, each participant will receive ranitidine or placebo with high nitrite/NDMA meals and ranitidine or placebo with low nitrite/NDMA meals', 'Separately, a previous study in 10 healthy volunteers showed that volunteers who received ranitidine had an increase in urinary NDMA excreted over 24 h. The level of increase was greater than would be expected from laboratory testing.', 'The study will use a prescription dose of ranitidine (300 mg) to test whether there is increased urinary NDMA excretion levels over 24-hours after ranitidine administration in comparison to placebo when participants are administered low nitrite/NDMA meals and when subjects are administered high nitrite/NDMA meals.', 'The ranitidine that will be used in this study has been tested twice (months apart) and shown to have stable NDMA levels well below the acceptable daily limit.', 'NDMA is a known environmental contaminant and found in water and foods, including meats, dairy products, and vegetables.', 'The US Food and Drug Administration (FDA) has found levels of NDMA in some ranitidine products similar to the levels you would expect to be exposed to if you ate common foods like grilled or smoked meats.', 'Clinical Study to Investigate the Urinary Excretion of N-nitrosodimethylamine (NDMA) After Ranitidine Administration.', 'This clinical study is being performed to determine if and how much NDMA is produced from ranitidine in the human body and whether nitrite-containing foods may increase formation of NDMA.', 'NDMA is classified as a probable human carcinogen (a substance that could cause cancer) based on results from laboratory tests.'}",{'NCT04397445'},NCT04397445
,,1,nitrite,FALSE,1,FALSE,FALSE,"On 4 different days, each participant will receive ranitidine or placebo with high nitrite/NDMA meals and ranitidine or placebo with low nitrite/NDMA meals","{'On 4 different days, each participant will receive ranitidine or placebo with high nitrite/NDMA meals and ranitidine or placebo with low nitrite/NDMA meals', 'The study will use a prescription dose of ranitidine (300 mg) to test whether there is increased urinary NDMA excretion levels over 24-hours after ranitidine administration in comparison to placebo when participants are administered low nitrite/NDMA meals and when subjects are administered high nitrite/NDMA meals.', 'This clinical study is being performed to determine if and how much NDMA is produced from ranitidine in the human body and whether nitrite-containing foods may increase formation of NDMA.'}",{'NCT04397445'},NCT04397445
,,1,nitrites,FALSE,1,FALSE,FALSE,"Other laboratory experiments suggest a combination of nitrites, such as found in processed meats, and an acidic environment may increase NDMA formation, however the levels of nitrites tested were very high.","{'Other laboratory experiments suggest a combination of nitrites, such as found in processed meats, and an acidic environment may increase NDMA formation, however the levels of nitrites tested were very high.'}",{'NCT04397445'},NCT04397445
1,,,jmt101,FALSE,1,FALSE,FALSE,"This study is a Phase Ib, open label, multi-center study of to evaluate the safety and efficacy of JMT101 combined with EGFR-TKIs (Afatinib or Osimertinib) in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations","{'This study is a Phase Ib, open label, multi-center study of to evaluate the safety and efficacy of JMT101 combined with EGFR-TKIs (Afatinib or Osimertinib) in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations', 'A Phase Ib,Open Label,Multi-center Study to Assess the Efficacy and Safety of JMT101 Combined With Afatinib (or Osimertinib) in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations.'}",{'NCT04448379'},NCT04448379
1,,,nbe-002,FALSE,1,FALSE,FALSE,"This first-in-human study will evaluate the recommended dose for further clinical development, safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and pharmacodynamics of NBE-002, a novel anti-ROR1 antibody-drug conjugate, in patients with advanced solid tumors","{'This first-in-human study will evaluate the recommended dose for further clinical development, safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and pharmacodynamics of NBE-002, a novel anti-ROR1 antibody-drug conjugate, in patients with advanced solid tumors', 'A First-in-Human, Phase 1/2 Study of NBE-002, an Anti-ROR1 Antibody Drug Conjugate, in Patients With Advanced Solid Tumors.'}",{'NCT04441099'},NCT04441099
1,,,ketotifen,FALSE,1,FALSE,FALSE,"The objective of our study was to evaluate the expected cardioprotective effects of ketotifen due to its activity as an iron-chelating agent previously uncovered by us in the in vitro chemical test which included in the study, when used in patients receiving anthracyclines for the treatment of breast cancer.","{'The objective of our study was to evaluate the expected cardioprotective effects of ketotifen due to its activity as an iron-chelating agent previously uncovered by us in the in vitro chemical test which included in the study, when used in patients receiving anthracyclines for the treatment of breast cancer.', '55 patients received their standard therapy (anthracycline-containing chemotherapy without ketotifen).', 'Ketotifen: Novel Use as a Cardioprotective Agent in Breast Cancer Patients Receiving Anthracycline-containing Chemotherapy as Well as the Potential Beneficial Effects of Ketotifen in the Hypothetical Management of COVID-19.', 'Ketotifen Group:', 'Ketotifen will be given orally as one tablet (1 mg/tablet) 3 times daily, before and during the chemotherapeutic cycle for 6 cycles of treatment.', '56 patients received anthracycline-containing chemotherapy plus ketotifen as a cardioprotective agent.'}",{'NCT04435028'},NCT04435028
1,,,ap-325,FALSE,1,FALSE,FALSE,"The study objective is to investigate the efficacy and safety of repeat oral dosing of the investigational medicinal product (IMP) AP-325 for the treatment of peripheral post-surgical neuropathic pain (PPNP) after breast surgery (breast cancer interventions), chest surgery (i.e. thoracotomy, video assisted thoracoscopy and sternotomy) or groin hernia repair (i.e. femoral hernia repairs and inguinal hernia repairs)","{'The study objective is to investigate the efficacy and safety of repeat oral dosing of the investigational medicinal product (IMP) AP-325 for the treatment of peripheral post-surgical neuropathic pain (PPNP) after breast surgery (breast cancer interventions), chest surgery (i.e. thoracotomy, video assisted thoracoscopy and sternotomy) or groin hernia repair (i.e. femoral hernia repairs and inguinal hernia repairs)', 'A Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of AP-325 in Subjects With Peripheral Post-surgical Neuropathic Pain.'}",{'NCT04429919'},NCT04429919
1,,,shr-a1811,FALSE,1,FALSE,FALSE,"This is an open-label, two-part study to evaluate the safety, tolerability, pharmacokinetics and immunogenicity of SHR-A1811 and preliminary anti-tumor efficacy in HER2 expressing or mutated advanced malignant solid tumor subjects","{'This is an open-label, two-part study to evaluate the safety, tolerability, pharmacokinetics and immunogenicity of SHR-A1811 and preliminary anti-tumor efficacy in HER2 expressing or mutated advanced malignant solid tumor subjects', 'A Phase 1 Multi-Country, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-A1811 in HER2 Expressing or Mutated Advanced Malignant Solid Tumor Subjects.'}",{'NCT04446260'},NCT04446260
,1,,bep800,FALSE,1,FALSE,FALSE,The investigators wish to study the effects of NVP-BEP800 on two different types of ALL (T and B-ALL),"{'The investigators wish to study the effects of NVP-BEP800 on two different types of ALL (T and B-ALL)', 'NVP-BEP800, a new HSP90 inhibitor, has particularly interesting therapeutic potential and represents hope in cancer pathologies.'}",{'NCT04437420'},NCT04437420
,1,,nvp,FALSE,1,FALSE,FALSE,The investigators wish to study the effects of NVP-BEP800 on two different types of ALL (T and B-ALL),"{'The investigators wish to study the effects of NVP-BEP800 on two different types of ALL (T and B-ALL)', 'NVP-BEP800, a new HSP90 inhibitor, has particularly interesting therapeutic potential and represents hope in cancer pathologies.'}",{'NCT04437420'},NCT04437420
1,,,nvp-bep800,FALSE,1,FALSE,FALSE,"Preclinical Project on the Traitment of Acute Lymphoblastique Leukemia With NVP-BEP800, an Inhibitor of the Heat Shock Protein HSP90.","{'Preclinical Project on the Traitment of Acute Lymphoblastique Leukemia With NVP-BEP800, an Inhibitor of the Heat Shock Protein HSP90.'}",{'NCT04437420'},NCT04437420
1,,,cc-99282,FALSE,1,FALSE,FALSE,CC-99282-CLL-001 study is a Phase IB dose escalation and expansion clinical study of CC-99282 administered in combination with Obinutuzumab in subjects with relapsed or refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma,"{'CC-99282-CLL-001 study is a Phase IB dose escalation and expansion clinical study of CC-99282 administered in combination with Obinutuzumab in subjects with relapsed or refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma', 'Phase 1b Study to Determine the Safety, Pharmacokinetics, and Preliminary Efficacy of the Combination of CC-99282 and Obinutuzumab in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.'}",{'NCT04434196'},NCT04434196
1,,,nc318,FALSE,1,FALSE,FALSE,"This research study is studying an investigational drug, NC318, as a possible treatment for subjects with advanced or metastatic non-small cell lung cancer in combination with chemotherapy","{'This research study is studying an investigational drug, NC318, as a possible treatment for subjects with advanced or metastatic non-small cell lung cancer in combination with chemotherapy', 'A Phase 1/2 Study of NC318 in Combination With Chemotherapy for Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer.'}",{'NCT04430933'},NCT04430933
1,,,glofitamab,FALSE,1,TRUE,FALSE,This study will evaluate the efficacy and safety of glofitamab in combination with gemcitabine plus oxaliplatin (Glofit-GemOx) compared with rituximab in combination with gemcitabine plus oxaliplatin (R-GemOx) in patients with R/R DLBCL,"{'This study will evaluate the efficacy and safety of glofitamab in combination with gemcitabine plus oxaliplatin (Glofit-GemOx) compared with rituximab in combination with gemcitabine plus oxaliplatin (R-GemOx) in patients with R/R DLBCL', 'A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Efficacy and Safety of Glofitamab in Combination With Gemcitabine Plus Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma.'}",{'NCT04408638'},NCT04408638
1,,,actinomycin-d,FALSE,1,FALSE,FALSE,"Low-risk GTN patients (FIGO score ≤ 6) are commonly treated with single agent treatment (methotrexate or actinomycin-D) The cure rate, assessed by hCG normalization, is obtained in 65 to 75% of patients with these agents GTN patients with resistance to these treatments are treated with another single agent drug or polychemotherapy regimens, such as EMA-CO or BEP regimen.","{'Low-risk GTN patients (FIGO score ≤ 6) are commonly treated with single agent treatment (methotrexate or actinomycin-D) The cure rate, assessed by hCG normalization, is obtained in 65 to 75% of patients with these agents GTN patients with resistance to these treatments are treated with another single agent drug or polychemotherapy regimens, such as EMA-CO or BEP regimen.'}",{'NCT04396223'},NCT04396223
,1,,ema,FALSE,1,FALSE,FALSE,"Low-risk GTN patients (FIGO score ≤ 6) are commonly treated with single agent treatment (methotrexate or actinomycin-D) The cure rate, assessed by hCG normalization, is obtained in 65 to 75% of patients with these agents GTN patients with resistance to these treatments are treated with another single agent drug or polychemotherapy regimens, such as EMA-CO or BEP regimen.","{'Low-risk GTN patients (FIGO score ≤ 6) are commonly treated with single agent treatment (methotrexate or actinomycin-D) The cure rate, assessed by hCG normalization, is obtained in 65 to 75% of patients with these agents GTN patients with resistance to these treatments are treated with another single agent drug or polychemotherapy regimens, such as EMA-CO or BEP regimen.'}",{'NCT04396223'},NCT04396223
1,,,5-fluorouracile,FALSE,1,FALSE,FALSE,"TWICE-IRI: Optimization of Second-line Therapy With Aflibercept, Irinotecan (Day 1 or Day 1,3), 5-Fluorouracile and Folinic Acid in Patients With Metastatic Colorectal Cancer.","{'TWICE-IRI: Optimization of Second-line Therapy With Aflibercept, Irinotecan (Day 1 or Day 1,3), 5-Fluorouracile and Folinic Acid in Patients With Metastatic Colorectal Cancer.'}",{'NCT04392479'},NCT04392479
,1,,5fluorouracile,TRUE,1,FALSE,FALSE,"Optimization of second-line therapy with aflibercept, irinotecan (day1 or day 1,3), 5fluorouracile and folinic acid in patients with metastatic colorectal cancer.","{'Optimization of second-line therapy with aflibercept, irinotecan (day1 or day 1,3), 5fluorouracile and folinic acid in patients with metastatic colorectal cancer.'}",{'NCT04392479'},NCT04392479
,,1,met,FALSE,1,FALSE,FALSE,"A Single-arm, Multicenter Study to Evaluate the Efficacy and Safety of TQ-B3139 in Subjects With MET-Altered Advanced Non-small Cell Lung Cancer.","{'A Single-arm, Multicenter Study to Evaluate the Efficacy and Safety of TQ-B3139 in Subjects With MET-Altered Advanced Non-small Cell Lung Cancer.'}",{'NCT04398940'},NCT04398940